Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM

ABSTRACT

This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing a pancreatic malfunction, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing a pancreatic malfunction.

This application is a continuation of U.S. Ser. No. 12/174,301 filedJul. 16, 2008, which is a continuation of U.S. Ser. No. 10/494,010 filedAug. 12, 2004 which is a 371 of International ApplicationPCT/EP2002/12075 filed Oct. 29, 2002, which claims the benefit ofEuropean Patent Applications No. 01125812.6 filed on Oct. 29, 2001 andEP02011 073.0 filed on May 17, 2002, the disclosure of which isincorporated herein in its entirety by reference.

DESCRIPTION

This invention relates to the use of nucleic acid sequences of the MAPkinase-interacting kinase (Mnk) gene family and amino acid sequencesencoded thereby, and to the use of these sequences or effectors of Mnknucleic acids or polypeptides, particularly Mnk kinase inhibitors andactivators, in the diagnosis, study, prevention, and treatment ofdiseases and disorders related to body-weight regulation andthermogenesis, for example, but not limited to, metabolic diseases suchas obesity, as well as related disorders such as eating disorder,cachexia, diabetes mellitus, hypertension, coronary heart disease,hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, andsleep apnea, and disorders related to ROS defence, such as diabetesmellitus, neurodegenerative disorders, and cancer, e.g. cancers of thereproductive organs.

There are several metabolic diseases of human and animal metabolism,eg., obesity and severe weight loss, that relate to energy imbalancewhere caloric intake versus energy expenditure is imbalanced. Obesity isone of the most prevalent metabolic disorder in the world. It is a stillpoorly understood human disease that becomes more and more relevant forwestern society. Obesity is defined as a body weight more than 20% inexcess of the ideal body weight, frequently resulting in a significantimpairment of health. It is associated with an increased risk forcardiovascular disease, hypertension, diabetes, hyperlipidemia and anincreased mortality rate. Besides severe risks of illness, individualssuffering from obesity are often isolated socially.

Obesity is influenced by genetic, metabolic, biochemical, psychological,and behavioral factors. As such, it is a complex disorder that must beaddressed on several fronts to achieve lasting positive clinicaloutcome. Since obesity is not to be considered as a single disorder butas a heterogeneous group of conditions with (potential) multiple causes,it is also characterized by elevated fasting plasma insulin and anexaggerated insulin response to oral glucose intake (Koltermann, J.Clin. Invest 65, 1980, 1272-1284). A clear involvement of obesity intype 2 diabetes mellitus can be confirmed (Kopelman, Nature 404, 2000,635-643).

The molecular factors regulating food intake and body weight balance areincompletely understood. Even if several candidate genes have beendescribed which are supposed to influence the homeostatic system(s) thatregulate body mass/weight, like leptin, VCPI, VCPL or the peroxisomeproliferator-activated receptor-gamma co-activator, the distinctmolecular mechanisms and/or molecules influencing obesity or bodyweight/body mass regulations are not known. In addition, severalsingle-gene mutations resulting in obesity have been described in mice,implicating genetic factors in the etiology of obesity (Friedman andLeibel, 1990, Cell 69: 217-220). In the obese mouse, a single genemutation (obese) results in profound obesity, which is accompanied bydiabetes (Friedman et. al., 1991, Genomics 11: 1054-1062).

Therefore, the technical problem underlying the present invention was toprovide for means and methods for modulating (pathological) metabolicconditions influencing thermogenesis, body-weight regulation and/orenergy homeostatic circuits. The solution to said technical problem isachieved by providing the embodiments characterized in the claims.

Accordingly, the present invention relates to genes with novel functionsin body-weight regulation, energy homeostasis, metabolism, and obesity.The present invention provides for a specific gene involved in theregulation of diseases and disorders related to body-weight regulationand thermogenesis, for example, but not limited to, metabolic diseasessuch as obesity, as well as related disorders such as eating disorder,cachexia, diabetes mellitus, hypertension, coronary heart disease,hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancersof the reproductive organs, and sleep apnea, and disorders related toROS defence, such as diabetes mellitus, neurodegenerative disorders, andcancer. The present invention describes the human Mnk genes as beinginvolved in those conditions mentioned above, in particular the humanMnk2 gene variants.

The term “GenBank Accession number” relates to National Center forBiotechnology Information (NCBI) GenBank database entries (Benson et al,Nucleic Acids Res. 28, 2000, 15-18).

Protein kinases are important molecules involved in the regulation ofmany cellular functions. The Drosophila melanogaster LK6serine/threonine kinase gene has been described as a short-lived kinasethat can associate with microtubules (J. Cell Sci. 1997 110(2):209-219).Genetic analysis in the development of the Drosophila compound eyesuggested a role in the modulation of the RAS signaling pathway(Genetics 2000 156(3):1219-1230). As described in this invention, theclosest human homologues of Drosophila LK6 kinase are the MAPkinase-interacting kinase 2 (Mnk2, for example the variants Mnk2a andMnk2b) and MAP kinase-interacting kinase 1 (Mnk1). All three proteinsare predominantly localized in the cytoplasm. Mnks are phosphorylated bythe pk42 MAP kinases Erk1 and Erk2 and the p38 MAP kinases. Thisphosphorylation is triggered in response to growth factors, phorbolesters and oncogenes like Ras and Mos as well as by stress signalingmolecules and cytokines. The phosphorylation of Mnk proteins stimulatesits kinase activity towards eukaryotic initiation factor 4E (EMBO J. 16:1909-1920 (1997), Mol Cell Bio119:1871-1880 (1999), Mol Cell Biol 21:743-754 (2001)). Phosphorylation of eukaryotic initiation factor 4E(eIF4E) results in a regulation of protein translation (Mol Cell Biol22: 5500-5511 (2001)).

There are different hypothesis describing the mode of stimulation of theprotein translation by Mnk proteins. Most publications described apositive stimulatory 3o effect on the cap-dependent protein translationupon activation of MAP kinase-interacting kinases. Thus, activation ofMnk proteins might lead to an indirect stimulation or regulation ofprotein translation, for example by the action on cytosolicphospholipase 2 alpha (BBA 1488:124-138, 2000).

Inhibitors of Mnk (referred to as CGP57380 and CGP052088) were describedin the prior art (see, Knauf et al., 2001, Mol. Cell. Biol. 21:5500,Tschopp et al., 2000, Mol Cell Bioi Res Comm 3:205 and Slentz-Kesler etal., 2000, Genomics 69:63). CGP052088 is a staurosporine derivative withan IC50 of 70 nM for inhibition of in vitro kinase activity of Mnk1.CGP57380 is a selective low-molecular weight, non cytotoxic inhibitor ofMnk2 (Mnk2a or Mnk2b) or Mnk1. The addition of CGP57380 to cell culturecells transfected with Mnk2 (Mnk2a or Mnk2b) or Mnk1 resulted in astrong reduction in phosphorylated eIF4E.

So far, it has not been described that Mnk kinases are involved in theregulation of body-weight and thermogenesis, and thus may be associatedwith metabolic diseases such as obesity, as well as related disorderssuch as eating disorder, cachexia, diabetes mellitus, hypertension,coronary heart disease, hypercholesterolemia, dyslipidemia,osteoarthritis, gallstones, and sleep apnea, and disorders related toROS defence, such as diabetes mellitus, neurodegenerative disorders, andcancer, e.g. cancers of the reproductive organs. In this application wedemonstrate that the correct gene doses of Mnk kinases are essential formaintenance of energy homeostasis. A genetic screen was used to identifythat mutation of Mnk kinase homologous genes causes obesity, reflectedby a significant increase of triglyceride content, the major energystorage substance. Furthermore, in this invention we relate to mutationsof Mnk kinases that affect the activity of uncoupling proteins (UCPs),thereby leading to an altered mitochondrial activity. We also relate tothe treatment of metabolic disorders with the Mnk-specific inhibitorCGP57380 and derivatives thereof.

In this invention we demonstrate that the correct gene dose of theDrosophila melanogaster homologue of Mnk is essential for maintenance ofenergy homeostasis in adult flies and for the activity of mitochondrialuncoupling protein. A genetic screen was used to identify that mutationof an Mnk homologous gene causes obesity in Drosophila melanogaster,reflected by a significant increase of triglyceride content, the majorenergy storage substance. In a second screen designed to identifyfactors that modulate activity of uncoupling protein, we discovered thatmutation of this Mnk homologous gene caused a reduction the activity ofuncoupling protein. Thus, the invention is also based on the findingthat the Drosophila homologue of Mnk is contributing to membranestability and/or function of organelles, preferably mitochondria. It wasfound that mutations in LK6 kinases affect the activity of uncouplingproteins (UCPs), thereby leading to an altered mitochondrial activity.

Further, we show that the mouse homologue of the Mnk2 gene is regulatedby fasting and by genetically induced obesity. Furthermore, the Mnk2mRNA is strongly upregulated during adipocyte differentiation in vitro(see EXAMPLES). This invention shows that Mnk2 transcripts are expressedin most mouse tissues but with highest expression levels in white (WAT)and brown adipose tissue (BAT). The expression in white adipose tissueis reduced by approx. 60% in fasted mice and in ob/ob mice. The analysisof actin-mMnk2DN transgenic mice showed that the ectopic expression ofmMnk2DN transgene (see Examples) leads to an clear increase inbodyweight. The effect seems to be diet-independent, as it can be seenon control diet as well as on high fat diet. Thus, we conclude that Mnk2is playing an important role in the regulation of body-weight.

In addition, we found that the relative expression levels of both humanMnk2 splice variants is the same for all tissues analysed. Both Mnk2variants show highest expression levels in human tissues relevant formetabolic disorders namely adipose and muscle tissue. Furthermore, bothMnk2 variants are upregulated during human adipocyte differentiation.Thus, we conclude that Mnk2 (or variants thereof) has a function in themetabolism of mature human adipocytes.

We also found that cellular triglyceride levels in Mnk2 overexpressingcells were significantly lower from day 4 to day 12 of adipogenesiscompared to that in the control cells. Furthermore, Mnk2 overexpressingcells were less effective at synthesising lipids from exogenous glucose.Consequently, the levels of insulin stimulated lipid synthesis aresignificantly lower at day 12 of adipogenesis when compared to controlcells. We also found that transport of exogenous fatty acids across theplasma membrane of Mnk2 overexpressing cells and hence esterification ofthese metabolites were considerably lower at day 12 of adipogenesis whencompared to control cells.

Polynucleotides encoding a protein with homologies to proteins of theMnk kinase family are suitable to investigate diseases and disorders asdescribed above. Discovery of molecules related to Mnk kinases satisfiesa need in the art by providing new compositions useful in diagnosis,treatment, and prognosis of diseases and disorders as described above.

Before the present proteins, nucleotide sequences, and methods aredescribed, it is understood that this invention is not limited to theparticular methodology, protocols, cell lines, vectors, and reagentsdescribed as these may vary. It is also to be understood that theterminology used herein is for the purpose of describing particularembodiments only, and is not intended to limit the scope of the presentinvention, which will be limited only by the appended claims. Unlessdefined otherwise, all technical and scientific terms used herein havethe same meanings as commonly understood by one of ordinary skill in theart to which this invention belongs. Although any methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the present invention, the preferred methods,devices, and materials are now described. All publications mentionedherein are incorporated herein by reference for the purpose ofdescribing and disclosing the cell lines, vectors, and methodologies,which are reported in the publications which might be used in connectionwith the invention. Nothing herein is to be construed as an admissionthat the invention is not entitled to antedate such disclosure.

The present invention discloses that Mnk homologous proteins areregulating the energy homeostasis and fat metabolism, especially themetabolism and storage of triglycerides, and polynucleotides, whichidentify and encode the proteins disclosed in this invention. Thepresent invention also discloses that Mnk homologous proteins aredirectly or indirectly involved in membrane stability and/or function oforganelles, in particular mitochondria, and polynucleotides, whichidentify and encode the proteins disclosed in this invention. Theinvention also relates to vectors, host cells, antibodies, andrecombinant methods for producing the polypeptides and polynucleotidesof the invention. The invention also relates to the use of thesesequences in the diagnosis, study, prevention, and treatment of diseasesand disorders related to body-weight regulation and thermogenesis, forexample, but not limited to, metabolic diseases such as obesity, as wellas related disorders such as eating disorder, cachexia, diabetesmellitus, hypertension, coronary heart disease, hypercholesterolemia,dyslipidemia, osteoarthritis, gallstones, and sleep apnea, and disordersrelated to ROS defence, such as diabetes mellitus, neurodegenerativedisorders, and cancer, e.g. cancers of the reproductive organs.

Mnk homologous proteins and nucleic acid molecules coding therefore areobtainable from insect or vertebrate species, e.g. mammals or birds.Particularly preferred are human Mnk homologous polypeptides and nucleicacids encoding such polypeptides, particularly polypeptides and nucleicacids encoding a human Mnk2 protein (splice variant Mnk2a, GenbankAccession No. AF237775 as shown in FIGS. 30 and 3E, or splice variantMnk2b, GenBank Accession AF237776 or No. NM_(—)017572.1, as shown inFIGS. 3F and 3G, Genbank Accession No. AF237775 is identical to formerlyGenbank Accession No. XM_(—)030637 which was removed at the submittersrequest; see a Clustal W multiple sequence alignment in FIG. 3B, seealso sequences in FIGS. 3D-G) or a human Mnk1 protein (Genbank AccessionNo. AB000409.1 and NM_(—)003684.2 as shown in FIGS. 3H and 3I); GenbankAccession No. AB000409 is identical to formerly Genbank Accession No.XM_(—)001600 which was removed at the submitters request; see a ClustalW multiple sequence alignment in FIG. 3C).

The invention particularly relates to a nucleic acid molecule encoding apolypeptide contributing to regulating the energy homeostasis and themetabolism of triglycerides, and/or contributing to membrane stabilityand/or function of organelles, wherein said nucleic acid moleculecomprises

(a) the nucleotide sequences of Genbank Accession Nos. AF237775,NM_(—)017572.1, AB000409.1, or NM_(—)003684.2, and/or the complementthereof,

(b) a nucleotide sequence which hybridizes at 50° C. in a solutioncontaining 1×SSC and 0.1% SDS to the nucleic acid molecule of (a),particularly a nucleic acid encoding the amino acid sequences as shownin FIG. 3,

(c) a sequence corresponding to the sequences of (a) or (b) within thedegeneration of the genetic code,

(d) a sequence which encodes a polypeptide which is at least 85%,preferably at least 90%, more preferably at least 95%, more preferablyat least 98% and up to 99.6% identical to the amino acid sequences shownin FIG. 3,

(e) a sequence which differs from the nucleic acid molecule of (a) to(d) by mutation and wherein said mutation causes an alteration,deletion, duplication or premature stop in the encoded polypeptide or

(f) a partial sequence of any of the nucleotide sequences of (a) to (e)having a length of at least 15 bases, preferably at least 20 bases, morepreferably at least 25 bases and most preferably at least 50 bases.

The invention is based on the finding that Mnk homologous proteins(herein referred to as Mnk), particularly Mnk2 (Mnk2a or Mnk2b) or Mnk1,and the polynucleotides encoding these, are involved in the regulationof triglyceride storage and therefore energy homeostasis. The presentinvention also discloses that Mnk homologous proteins are directly orindirectly involved in membrane stability and/or function of organelles,in particular mitochondria, and polynucleotides, which identify andencode the proteins disclosed in this invention. The invention describesthe use of compositions comprising the nucleotides, proteins oreffectors thereof, e.g. antibodies, aptamers, anti-sense molecules,ribozymes, RNAi molecules, peptides, low-molecular weight organicmolecules and other receptors recognizing the nucleic acid molecule orthe polypeptide, for the diagnosis, study, prevention, or treatment ofdiseases and disorders related to body-weight regulation andthermogenesis, for example, but not limited to, metabolic diseases suchas obesity, as well as related disorders such as eating disorder,cachexia, diabetes mellitus, hypertension, coronary heart disease,hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, andsleep apnea, and disorders related to ROS defence, such as diabetesmellitus, neurodegenerative disorders, and cancer, e.g. cancers of thereproductive organs.

Accordingly, the present invention relates to genes with novel functionsin body-weight regulation, energy homeostasis, metabolism, and obesity.To find genes with novel functions in energy homeostasis, metabolism,and obesity, a functional genetic screen was performed with the modelorganism Drosophila melanogaster (Melgen). Drosophila melanogaster isone of the most intensively studied organisms in biology and serves as amodel system for the investigation of many developmental and cellularprocesses common to higher eukaryotes, including humans (see, forexample, Adams et al., Science 287: 2185-2195 (2000)). The success ofDrosophila melanogaster as a model organism is largely due to the powerof forward genetic screens to identify the genes that are involved in abiological process (see, Johnston Nat Rev Genet. 3: 176-188 (2002);Rorth, Proc Natl Acad Sci U SA 93: 12418-12422 (1996)). One resource forscreening was a proprietary Drosophila melanogaster stock collection ofEP-lines. The P-vector of this collection has Gai4-UAS-binding sitesfused to a basal promoter that can transcribe adjacent genomicDrosophila sequences upon binding of Gal4 to UAS-sites. This enables theEP-line collection for overexpression of endogenous flanking genesequences. In addition, without activation of the UAS-sites, integrationof the EP-element into the gene is likely to cause a reduction of geneactivity, and allows determining its function by evaluating theloss-of-function phenotype.

Triglycerides are the most efficient storage for energy in cells, andare significantly increased in obese patients. In this invention, wehave used a genetic screen to identify, that mutations of Lk6 homologousgenes cause changes in the body weight which is reflected by asignificant change in the triglyceride levels. In order to isolate geneswith a function in energy homeostasis, several thousand EP-lines weretested for their triglyceride content after a prolonged feeding period.Lines with significantly changed triglyceride content were selected aspositive candidates for further analysis. In this invention, the contentof triglycerides of a pool of flies with the same genotype after feedingfor six days was analyzed using a triglyceride assay, as, for example,but not for limiting the scope of the invention, is described below inthe examples section. The change of triglyceride content due to the lossof a gene function suggests gene activities in energy homeostasis in adose dependent manner that controls the amount of energy stored astriglycerides.

The result of the triglyceride content analysis is shown in FIG. 1.Flies homozygous for EP(3)3333 and EP(3)3576 integrations were analyzedin the triglyceride assay. The average increase of triglyceride contentof the homozygous viable lines EP(3)3333 and EP(3)3576 is approx. 140%(FIG. 1). Therefore, the very likely loss of a gene activity in the genelocus 86F7 (estimated, chromosomal localisation where the EP-vector ofEP(3)3333 and EP(3)3576 flies is integrated) is responsible for changesin the metabolism of the energy storage triglycerides, thereforerepresenting in both cases an obese fly model. The increase oftriglyceride content due to the loss of a gene function suggests geneactivities in energy homeostasis in a dose dependent manner thatcontrols the amount of energy stored as triglycerides.

Nucleic acids encoding the Mnk protein of the present invention wereidentified using a plasmid-rescue technique. Genomic DNA sequences wereisolated that are localised directly 3′ to the EP(3)3333 and EP(3)3576integrations. Using those isolated genomic sequences public databaseslike Berkeley Drosophila Genome Project (GadFly; see also FlyBase (1999)Nucleic Acids Research 27:85-88) were screened thereby confirming theintegration side of EP(3)3333 in the 5′ region of a 5′ exon of the Mnkhomologous gene and EP(3)3576 in the 5′ region of an alternative 5′ exon(FIG. 2). FIG. 2 shows the molecular organisation of this locus. GenomicDNA sequence is represented by the assembly as a black dotted line inthe middle that includes the integration site of EP(3)3333 andEP(3)3576. Numbers represent the coordinates of the genomic DNA(starting at position 7544500 on chromosome 3R). Grey bars on the two“cDNA”-lines represent the predicted genes (GadFly & Magpie), and greysymbols on the “P-Elements”-line the EP-vector integration sites.Predicted exons of gene CG17342 are shown as dark grey bars andpredicted introns as light grey bars.

Lk6 (the Mnk homologous gene in Drosophila) encodes for a gene that ispredicted by GadFly sequence analysis programs (GadFly Accession NumberCG17342). No functional data described the regulation of obesity andmetabolic diseases are available in the prior art for the genes shown inFIG. 3, referred to as Mnk in the present invention.

It is also preferred that the nucleic acid molecule encodes apolypeptide contributing to membrane stability and/or function oforganelles and represents a protein of Drosophila which has been foundto be able to modify UCPs, see also appended examples. As demonstratedin the appended examples, the here described polypeptide (and encodingnucleic acid molecule) was able to modify, e.g. enhance a specific eyephenotype in Drosophila which was due to the overexpression of theDrosophila melanogaster gene dUCPy. The overexpression of dUCPy (withhomology to human UCPs) in the compound eye of Drosophila led to aclearly visible eye defect which can be used as a “read-out” for agenetical “modifier screen”.

In said “modifier screen” thousands of different genes are mutagenizedto modify their expression in the eye. Should one of the mutagenizedgenes interact with dUCPy and modify its activity an enhancement orsuppression of the eye defect will occur. Since such flies are easily todiscern they can be selected to isolate the interacting gene. As shownin the appended examples, a gene was deduced that can enhance the eyedefect induced by the activity of dUCPy. This gene is called the LK6gene of Drosophila with high homologies to the human Mnk proteins, asdescribed above. It is envisaged that mutations in the herein describedMnk-polypeptides (and genes) lead to phenotypic and/or physiologicalchances which may comprise a modified and altered mitochondrialactivity. This, in turn, may lead to, inter alia, an altered energymetabolism, altered thermogenesis and/or altered energy homeostasis. Asshown in the appended examples, a gene was deduced that can enhance theeye defect induced by the activity of dUCPy.

Mnk homologous proteins and nucleic acid molecules coding therefor areobtainable from insect or vertebrate species, e.g. mammals or birds.Particularly preferred are nucleic acids encoding the human Lk6/Mnkhomologs, particularly Mnk2 variants (Mnk2a or Mnk2b) or Mnk1. Thepresent invention is describing a polypeptide comprising the amino acidsequence of Mnk, particularly Mnk2 variants (Mnk2a or Mnk2b) or Mnk1. Acomparison (Ciustal×1.8) between the Mnk proteins of different species(human and Drosophila) was conducted and is shown in FIG. 3A. Based uponhomology, Mnk protein of the invention and each homologous protein orpeptide may share at least some activity.

In a particular embodiment, the invention encompasses the polynucleotidecomprising the nucleic acid sequence of GenBank Accession NumberAF237775, NM_(—)017572.1, AB000409.1, or NM_(—)003684.2. It will beappreciated by those skilled in the art that as a result of thedegeneracy of the genetic code, a multitude of nucleotide sequencesencoding Mnk, some bearing minimal homology to the nucleotide sequencesof any known and naturally occurring gene, may be produced. Thus, theinvention contemplates each and every possible variation of nucleotidesequence that could be made by selecting combinations based on possiblecodon choices. These combinations are made in accordance with thestandard triplet genetic code as applied to the nucleotide sequences ofnaturally occurring Mnk, and all such variations are to be considered asbeing specifically disclosed. Although nucleotide sequences which encodeMnk and its variants are preferably capable of hybridising to thenucleotide sequences of the naturally occurring Mnk under appropriatelyselected conditions of stringency, it may be advantageous to producenucleotide sequences encoding Mnk or its derivatives possessing asubstantially different codon usage. Codons may be selected to increasethe rate at which expression of the peptide occurs in a particularprokaryotic or eukaryotic host in accordance with the frequency withwhich particular codons are utilised by the host. Other reasons forsubstantially altering the nucleotide sequence encoding Mnk and itsderivatives without altering the encoded amino acid sequences includethe production of RNA transcripts having more desirable properties, suchas a greater half-life, than transcripts produced from the naturallyoccurring sequences. The invention also encompasses production of DNAsequences, or portions thereof, which encode Mnk and its derivatives,entirely by synthetic chemistry. After production, the syntheticsequence may be inserted into any of the many available expressionvectors and cell systems using reagents that are well known in the artat the time of the filing of this application. Moreover, syntheticchemistry may be used to introduce mutations into a sequence encodingMnk any portion thereof.

Also encompassed by the invention are polynucleotide sequences that arecapable of hybridizing to the claimed nucleotide sequences, and inparticular, those shown in GenBank Accession Numbers AF237775,NM_(—)017572.1, AB000409.1, or NM_(—)003684.2, under various conditionsof stringency. Hybridization conditions are based on the meltingtemperature (Tm) of the nucleic acid binding complex or probe, as taughtin Wahl, G. M. and S. L. Berger (1987: Methods Enzymol. 152:399-407) andKimmel, A. R. (1987; Methods Enzymol. 152:507-511), and may be used at adefined stringency. Preferably, hybridization under stringent conditionsmeans that after washing for 1 h with 1×SSC and 0.1% SDS at 50° C.,preferably at 55° C., more preferably at 62° C. and most preferably at68° C., particularly for 1 h in 0.2×SSC and 0.1% SDS at 50° C.,preferably at 55° C., more preferably at 62° C. and most preferably at68° C., a positive hybridization signal is observed. Altered nucleicacid sequences encoding Mnk which are encompassed by the inventioninclude deletions, insertions, or substitutions of different nucleotidesresulting in a polynucleotide that encodes the same or a functionallyequivalent Mnk.

The encoded proteins may also contain deletions, insertions, orsubstitutions of amino acid residues, which produce a silent change andresult in a functionally equivalent Mnk. Deliberate amino acidsubstitutions may be made on the basis of similarity in polarity,charge, solubility, hydrophobicity, hydrophilicity, and/or theamphipathic nature of the residues as long as the biological activity ofMnk is retained. For example, negatively charged amino acids may includeaspartic acid and glutamic acid; positively charged amino acids mayinclude lysine and arginine; and amino acids with uncharged polar headgroups having similar hydrophilicity values may include leucine,isoleucine, and valine; glycine and alanine; asparagine and glutamine;serine and threonine; phenylalanine and tyrosine.

Also included within the scope of the present invention are alleles ofthe genes encoding Mnk. As used herein, an “allele” or “allelicsequence” is an alternative form of the gene, which may result from atleast one mutation in the nucleic acid sequence. Alleles may result inaltered mRNAs or polypeptides whose structures or function may or maynot be altered. Any given gene may have none, one, or many allelicforms. Common mutational changes, which give rise to alleles, aregenerally ascribed to natural deletions, additions, or substitutions ofnucleotides. Each of these types of changes may occur alone, or incombination with the others, one or more times in a given sequence.Methods for DNA sequencing which are well known and generally availablein the art may be used to practice any embodiments of the invention. Themethods may employ such enzymes as the Klenow fragment of DNA polymeraseI, SEQUENASE DNA Polymerase (US Biochemical Corp, Cleveland Ohio), Taqpolymerase (Perkin Elmer), thermostable T7 polymerase (Amersham,Chicago, Ill.), or combinations of recombinant polymerases andproof-reading exonucleases such as the ELONGASE Amplification System(GIBCO/BRL, Gaithersburg, Md.). Preferably, the process is automatedwith machines such as the Hamilton MICROLAB 2200 (Hamilton, Reno Nev.),Peltier thermal cycler (PTC200; MJ Research, Watertown, Mass.) and theABI 377 DNA sequencers (Perkin Elmer). The nucleic acid sequencesencoding Mnk may be extended utilising a partial nucleotide sequence andemploying various methods known in the art to detect upstream sequencessuch as promoters and regulatory elements. For example, one method whichmay be employed, “restriction-site” PCR, uses universal primers toretrieve unknown sequence adjacent to a known locus (Sarkar, G. (1993)PCR Methods Applic. 2:318-322). Inverse PCR may also be used to amplifyor extend sequences using divergent primers based on a known region(Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). Another 35method which may be used is capture PCR which involves PCR amplificationof DNA fragments adjacent to a known sequence in human and yeastartificial chromosome DNA (Lagerstrom, M. et al. (PCR Methods Applic. 1:111-119). Another method which may be used to retrieve unknown sequencesis that of Parker, J. D. et al. (1991; Nucleic Acids Res. 19:3055-3060).Additionally, one may use PCR, nested primers, and PROMOTERFINDERlibraries to walk in genomic DNA (Clontech, Palo Alto, Calif.). Thisprocess avoids the need to screen libraries and is useful in findingintron/exon junctions.

When screening for full-length cDNAs, it is preferable to use librariesthat have been size-selected to include larger cDNAs. Also,random-primed libraries are preferable, in that they will contain moresequences, which contain the 5′ regions of genes. Use of a randomlyprimed library may be especially preferable for situations in which anoligo d(T) library does not yield a full-length cDNA. Genomic librariesmay be useful for extension of sequence into the 5′ and 3′non-transcribed regulatory regions. Capillary electrophoresis systems,which are commercially available, may be used to analyse the size orconfirm the nucleotide sequence of sequencing or PCR products. Inparticular, capillary sequencing may employ flowable polymers forelectrophoretic separation, four different fluorescent dyes (one foreach nucleotide) which are laser activated, and detection of the emittedwavelengths by a charge coupled devise camera. Output/light intensitymay be converted to electrical signal using appropriate software (e.g.GENOTYPER and SEQUENCE NAVIGATOR, Perkin Elmer) and the entire processfrom loading of samples to computer analysis and electronic data displaymay be computer controlled. Capillary electrophoresis is especiallypreferable for the sequencing of small pieces of DNA, which might bepresent in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences orfragments thereof which encode Mnk, or fusion proteins or functionalequivalents thereof, may be used in recombinant DNA molecules to directexpression of Mnk in appropriate host cells. Due to the inherentdegeneracy of the genetic code, other DNA sequences, which encodesubstantially the same, or a functionally equivalent amino acid sequencemay be produced and these sequences may be used to clone and expressMnk. As will be understood by those of skill in the art, it may beadvantageous to produce Mnk-encoding nucleotide sequences possessingnon-naturally occurring codons. For example, codons preferred by aparticular prokaryotic or eukaryotic host can be selected to increasethe rate of protein expression or to produce a recombinant RNAtranscript having desirable properties, such as a half-life, which islonger than that of a transcript generated from the naturally occurringsequence. The nucleotide sequences of the present invention can beengineered using methods generally known in the art in order to alterMnk encoding sequences for a variety of reasons, including but notlimited to, alterations which modify the cloning, processing, and/orexpression of the gene product. DNA shuffling by random fragmentationand PCR reassembly of gene fragments and synthetic oligonucleotides maybe used to engineer the nucleotide sequences. For example, site-directedmutagenesis may be used to insert new restriction sites, alterglycosylation patterns, change codon preference, produce splicevariants, or introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, orrecombinant nucleic acid sequences encoding Mnk may be ligated to aheterologous sequence to encode a fusion protein. For example, to screenpeptide libraries for inhibitors of Mnk activities, it may be useful toconstruct chimeric Mnk proteins that can be recognised by a commerciallyavailable antibodies. A fusion protein may also be engineered to containa cleavage site located between the Mnk encoding sequence and theheterologous protein sequences, so that Mnk may be cleaved and purifiedaway from the heterologous moiety. In another embodiment, sequencesencoding Mnk may be synthesised, in whole or in part, using chemicalmethods well known in the art (see Caruthers et al. (1980) Nucl. AcidsRes. Symp. Ser. 7:215-223, Horn et al. (1980) Nucl. Acids Res. Symp.Ser. 7:225-232). Alternatively, the proteins themselves may be producedusing chemical methods to synthesise the amino acid sequence of Mnk, ora portion thereof. For example, peptide synthesis can be performed usingvarious solid-phase techniques (Roberge et al. (1995) Science269:202-204) and automated synthesis may be achieved, for example, usingthe ABI431A peptide synthesiser (Perkin Elmer). The newly synthesisedpeptide may be substantially purified by preparative high performanceliquid chromatography (e.g., Creighton, T. (1983) Proteins, Structuresand Molecular Principles, WH Freeman and Co., New York, N.Y.). Thecomposition of the synthetic peptides may be confirmed by amino acidanalysis or sequencing (e.g., the Edman degradation procedure;Creighton, supra). Additionally, the amino acid sequences of Mnk, or anypart thereof, may be altered during direct synthesis and/or combinedusing chemical methods with sequences from other proteins, or any partthereof, to produce a variant polypeptide.

In order to express a biologically active Mnk, the nucleotide sequencesencoding Mnk functional equivalents, may be inserted into appropriateexpression vectors, i.e., a vector, which contains the necessaryelements for the transcription and translation of the inserted codingsequence. Methods, which are well known to those skilled in the art, maybe used to construct expression vectors containing sequences encodingMnk and appropriate transcriptional and translational control elements.These methods include in vitro recombinant DNA techniques, synthetictechniques, and in vivo genetic recombination. Such techniques aredescribed in Sambrook, J. et al. (1989) Molecular Cloning, A LaboratoryManual, Cold Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. etal. (1989) Current Protocols in Molecular Biology, John Wiley & Sons,New York, N.Y.

Regulatory elements include for example a promoter, an initiation codon,a stop codon, a mRNA stability regulatory element, and a polyadenylationsignal. Expression of a polynucleotide can be assured by (i)constitutive promoters such as the Cytomegalovirus (CMV)promoter/enhancer region, (ii) tissue specific promoters such as theinsulin promoter (see, Soria et al., 2000, Diabetes 49:157), SOX2 genepromoter (see Li et al., 1998, Curr. Biol. 8:971-4), Msi-1 promoter (seeSakakibara et al., 1997, J. Neuroscience 17:8300-8312), alpha-cardiamyosin heavy chain promoter or human atrial natriuretic factor promoter(Kiug et al., 1996, J. Clin. Invest 98:216-24; Wu et al., 1989, J. Biol.Chem. 264:6472-79) or (iii) inducible promoters such as the tetracyclineinducible system. Expression vectors can also contain a selection agentor marker gene that confers antibiotic resistance such as the neomycin,hygromycin or puromycin resistance genes. These methods include in vitrorecombinant DNA techniques, synthetic techniques, and in vivo geneticrecombination. Such techniques are described in Sambrook, J. et al.(1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press,Plainview, N.Y. and Ausubel, F. M. et al. (1989) Current Protocols inMolecular Biology, John Wiley & Sons, New York, N.Y. In a furtherembodiment of the invention, natural, modified or recombinant nucleicacid sequences encoding the proteins of the invention and homologousproteins may be ligated to a heterologous sequence to encode a fusionprotein.

A variety of expression vector/host systems may be utilized to containand express sequences encoding the proteins or fusion proteins. Theseinclude, but are not limited to, micro-organisms such as bacteriatransformed with recombinant bacteriophage, plasmid or cosmid DNAexpression vectors; yeast transformed with yeast expression vectors;insect cell systems infected with virus expression vectors (e.g.,baculovirus, adenovirus, adeno-associated virus, lentivirus,retrovirus); plant cell systems transformed with virus expressionvectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus,TMV) or with bacterial expression vectors (e.g., Ti or PBR322 plasmids);or animal cell systems.

The “control elements” or “regulatory sequences” are thosenon-translated regions of the vectors, e.g. enhancers, promoters, 5′ and3′ untranslated regions, which interact with host cellular proteins tocarry out transcription and translation. Such elements may vary in theirstrength and specificity. Depending on the vector system and hostutilised, any number of suitable transcription and translation elements,including constitutive and inducible promoters, may be used. Forexample, when cloning in bacterial systems, inducible promoters such asthe hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene,LaJolla, Calif.) or PSPORT1 plasmid (Gibco BRL) and the like may beused. The baculovirus polyhedrin promoter may be used in insect cells.Promoters and enhancers derived from the genomes of plant cells (e.g.,heat shock, RUBISCO; and storage protein genes) or from plant viruses(e.g., viral promoters and leader sequences) may be cloned into thevector. In mammalian cell systems, promoters from mammalian genes orfrom mammalian viruses are preferable. If it is necessary to generate acell line that contains multiple copies of the sequences encoding Mnk,vectors based on SV40 or EBV may be used with an appropriate selectablemarker.

In bacterial systems, a number of expression vectors may be selecteddepending upon the use intended for Mnk. For example, when largequantities of Mnk are needed for the induction of antibodies, vectors,which direct high level expression of fusion proteins that are readilypurified, may be used. Such vectors include, but are not limited to, themultifunctional E. coli cloning and expression vectors such as theBLUESCRIPT phagemid (Stratagene), in which the sequence encoding Mnk maybe ligated into the vector in frame with sequences for theamino-terminal Met and the subsequent 7 residues of r3-galactosidase sothat a hybrid protein is produced; piN vectors (Van Heeke, G. and S. M.Schuster (1989) J. Bioi. Chem. 264:5503-5509); and the like. Vectors ofthe pGEX series (Amersham Biosciencies, Uppsala, Sweden) may also beused to express foreign polypeptides as fusion proteins with GlutathioneS-Transferase (GST). In general, such fusion proteins are soluble andcan easily be purified from lysed cells by adsorption toglutathione-agarose beads followed by elution in the presence of freeglutathione. Proteins made in such systems may be designed to includeheparin, thrombin, or factor XA protease cleavage sites so that thecloned polypeptide of interest can be released from the GST moiety atwill. In the yeast, Saccharomyces cerevisiae, a number of vectorscontaining constitutive or inducible promoters such as alpha factor,alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al.,(supra) and Grant et al. (1987) Methods Enzymol. 153:516-544.

In cases where plant expression vectors are used, the expression ofsequences encoding Mnk may be driven by any of a number of promoters.For example, viral promoters such as the 35S and 19S promoters of CaMVmay be used alone or in combination with the omega leader sequence fromTMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plantpromoters such as the small subunit of RUBISCO or heat shock promotersmay be used (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R.et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) ResultsProbl. Cell Differ. 17:85-1 05). These constructs can be introduced intoplant cells by direct DNA transformation or pathogen-mediatedtransfection. Such techniques are described in a number of generallyavailable reviews (see, for example, Hobbs, S. or Murry, L. E. in McGrawHill Yearbook of Science and Technology (1992) McGraw Hill, New York,N.Y.; pp. 191-196).

An insect system may also be used to express Mnk. For example, in onesuch system, Autographa californica nuclear polyhedrosis virus (AcNPV)is used as a vector to express foreign genes in Spodoptera frugiperdacells or in Trichoplusia larvae. The sequences encoding Mnk may becloned into a non-essential region of the virus, such as the polyhedringene, and place under control of the polyhedrin promoter. Successfulinsertions of Mnk will render the polyhedrin gene inactive and producerecombinant virus lacking coat protein. The recombinant viruses may thenbe used to infect, for example, S. frugiperda cells of Trichoplusialarvae in which Mnk may be expressed (Engelhard, E. K. et al. (1994)Proc. Nat. Acad. Sci. 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems maybe utilised. In cases where an adenovirus is used as an expressionvector, sequences encoding Mnk may be ligated into an adenovirustranscription/translation complex consisting of the late promoter andtripartite leader sequence. Insertion in a non-essential E1 or E3 regionof the viral genome may be used to obtain viable viruses which arecapable of expressing Mnk in infected host cells (Logan, J. and Shenk,T. (1984) Proc. Natl. Acad. Sci. 81:3655-3659). In addition,transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer,may be used to increase expression in mammalian host cells.

Specific initiation signals may also be used to achieve more efficienttranslation of sequences encoding Mnk. Such signals include the ATGinitiation codon and adjacent sequences. In cases where sequencesencoding Mnk, its initiation codons, and upstream sequences are insertedinto the appropriate expression vector, no additional transcriptional ortranslational control signals may be needed. However, in cases whereonly coding sequence, or a portion thereof, is inserted, exogenoustranslational control signals including the ATG initiation codon shouldbe provided. Furthermore, the initiation codon should be in the correctreading frame to ensure translation of the entire insert. Exogenoustranslational elements and initiation codons may be of various origins,both natural and synthetic. The efficiency of expression may be enhancedby the inclusion of enhancers which are appropriate for the particularcell system which is used, such as those described in the literature(Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162).

In addition, a host cell strain may be chosen for its ability tomodulate the expression of the inserted sequences or to process theexpressed protein in the desired fashion. Such modifications of thepolypeptide include, but are not limited to, acetylation, carboxylation,glycosylation, phosphorylation, lipidation, and acylation.Post-translational processing which cleaves a “prepro” form of theprotein may also be used to facilitate correct insertion, folding and/orfunction. Different host cells such as CHO, He La, MOCK, HEK293, andWI38, which have specific cellular machinery and characteristicmechanisms for such post-translational activities, may be chosen toensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stableexpression is preferred. For example, cell lines, which stably expressMnk may be transformed using expression vectors which may contain viralorigins of replication and/or endogenous expression elements and aselectable marker gene on the same or on a separate vector. Followingthe introduction of the vector, cells may be allowed to grow for 1-2days in an enriched media before they are switched to selective media.The purpose of the selectable marker is to confer resistance toselection, and its presence allows growth and recovery of cells, whichsuccessfully express the introduced sequences. Resistant clones ofstably transformed cells may be proliferated using tissue culturetechniques appropriate to the cell type. Any number of selection systemsmay be used to recover transformed cell lines. These include, but arenot limited to, the herpes simplex virus thymidine kinase (Wigler, M. etal. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy,I. et al. (1980) Cell 22:817-23) genes, which can be employed in tk⁻ oraprt⁻ cells, respectively. Also, antimetabolite, antibiotic or herbicideresistance can be used as the basis for selection; for example, dhfrwhich confers resistance to methotrexate (Wigler, M. et al. (1980) Proc.Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to theaminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) J.Mol. Bioi. 150:1-14) and als or pat, which confer resistance tochlorsulfuron and phosphinotricin acetyltransferase, respectively(Murry, supra). Additional selectable genes have been described, forexample, trpB, which allows cells to utilise indole in place oftryptophan, or hisD, which allows cells to utilise histinol in place ofhistidine (Hartman, S. C. and R. C. Mulligan (1988) Proc. Natl. Acad.Sci. 85:804 7-51). Recently, the use of visible markers has gainedpopularity with such markers as anthocyanins, β-glucuronidase and itssubstrate GUS, and luciferase and its substrate luciferin, being widelyused not only to identify transformants, but also to quantify the amountof transient or stable protein expression attributable to a specificvector system (Rhodes, C. A. et al. (1995) Methods Mol. Biol. 55:121-131).

In vivo, the enzymatic kinase activity of the unmodified polypeptides ofMnk towards a substrate can be enhanced by appropriate stimuli,triggering the phosphorylation of Mnk. This may be induced in thenatural context by extracellular or intracellular stimuli, such assignaling molecules or environmental influences. One may generate asystem containing actived Mnk, may it be an organism, a tissue, aculture of cells or cell-free environment, by exogenously applying thisstimulus or by mimicking this stimulus by a variety of the techniques,some of them described further below. A system containing activated Mnkmay be produced (i) for the purpose of diagnosis, study, prevention, andtreatment of diseases and disorders related to body-weight regulationand thermogenesis, for example, but not limited to, metabolic diseasessuch as obesity, as well as related disorders such as eating disorder,cachexia, diabetes mellitus, hypertension, coronary heart disease,hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, andsleep apnea, and disorders related to ROS defence, such as diabetesmellitus, neurodegenerative disorders, and cancer, e.g. cancers of thereproductive organs, (ii) for the purpose of identifying or validatingtherapeutic candidate agents, pharmaceuticals or drugs that influencethe genes of the invention or their encoded polypeptides, (iii) for thepurpose of generating cell lysates containing activated polypeptidesencoded by the genes of the invention, (iv) for the purpose of isolatingfrom this source activated polypeptides encoded by the genes of theinvention.

In one embodiment of the invention, one may produce activated Mnkindependent of the natural stimuli for the above said purposes by, forexample, but not limited to, (i) an agent that mimics the naturalstimulus; (ii) an agents, that acts downstream of the natural stimulus,such as activators of the MAP kinase pathway, phorbol ester, anisomycin,constitutive active alleles of the MAP kinase kinase kinases, of the MAPkinase kinases, of the MAP kinase or Mnk itself as they are described ormay be developed; (iii) by introduction of single or multiple amino acidsubstitutions, deletions or insertions within the sequence of Mnk toyield constitutive active forms; (iv) by the use of isolated fragmentsof Mnk. In addition, one may generate enzymatically active Mnk in anectopic system, prokaryotic or eukaryotic, in vivo or in vitro, byco-transfering the activating components to this system. These could be,for example, but not limited to, components of the MAP kinase pathwaysuch as constitutive active alleles of the MAP kinase kinases Mek1 orMkk6, together with the MAP kinases ERK1 or ERK2 or the p38 MAPKisoforms. For example, one may activate isolated Mnk protein in solutionwith a mutant polypeptide of Mek1 containing the amino acidsubstitutions S218D and S222E together with isolated ERK2 kinase in thepresence of 1.0 mM adenosine triphosphate and suitable buffer conditionssuch as 50 mM N-(2-Hydroxyethyl)-piperazine-N′-(2-ethanesuflonicacid)/potassium hydroxide pH 7.4, 5 mM magnesium chloride, 0.5 mMdithiothreitol (see FIG. 14).

Although the presence/absence of marker gene expression suggests thatthe gene of interest is also present, its presence and expression mayneed to be confirmed. For example, if the sequences encoding Mnk areinserted within a marker gene sequence, recombinant cells containingsequences encoding Mnk can be identified by the absence of marker genefunction. Alternatively, a marker gene can be placed in tandem withsequences encoding Mnk under the control of a single promoter.Expression of the marker gene in response to induction or selectionusually indicates expression of the tandem gene as well. Alternatively,host cells, which contain the nucleic acid sequences encoding Mnk andexpress Mnk, may be identified by a variety of procedures known to thoseof skill in the art. These procedures include, but are not limited to,DNA-DNA, or DNA-RNA hybridisation and protein bioassay or immunoassaytechniques, which include membrane, solution, or chip based technologiesfor the detection and/or quantification of nucleic acid or protein.

The presence of polynucleotide sequences encoding Mnk can be detected byDNA-DNA or DNA-RNA hybridisation or amplification using probes orportions or fragments of polynucleotides encoding Mnk. Nucleic acidamplification based assays involve the use of oligonucleotides oroligomers based on the sequences encoding Mnk to detect transformantscontaining DNA or RNA encoding Mnk. As used herein “oligonucleotides” or“oligomers” refer to a nucleic acid sequence of at least about 10nucleotides and as many as about 60 nucleotides, preferably about 15 to30 nucleotides, and more preferably about 20-25 nucleotides, which canbe used as a probe or amplimer.

A variety of protocols for detecting and measuring the expression ofMnk, using either polyclonal or monoclonal antibodies specific for theprotein are known in the art. Examples include enzyme-linkedimmunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescenceactivated cell sorting (FAGS). A two-site, monoclonal-based immunoassayutilising monoclonal antibodies reactive to two non-interfering epitopeson Mnk is preferred, but a competitive binding assay may be employed.These and other assays are described, among other places, in Hampton, R.et al. (1990; Serological Methods, a Laboratory Manual, APS Press, StPaul, Minn.) and Maddox, D. E. et al. (1983; J. Exp. Med. 158:1211-1216).

A wide variety of labels and conjugation techniques are known by thoseskilled in the art and may be used in various nucleic acid and aminoacid assays. Means for producing labelled hybridisation or PCR probesfor detecting sequences related to polynucleotides encoding Mnk includeoligo-labelling, nick translation, end-labelling or PCR amplificationusing a labelled nucleotide.

Alternatively, the sequences encoding Mnk, or any portions thereof maybe cloned into a vector for the production of an mRNA probe. Suchvectors are known in the art, are commercially available, and may beused to synthesise RNA probes in vitro by addition of an appropriate RNApolymerase such as T7, T3, or SP6 and labelled nucleotides. Theseprocedures may be conducted using a variety of commercially availablekits (Pharmacia & Upjohn, (Kalamazoo, Mich.); Promega (Madison Wis.);and U.S. Biochemical Corp., (Cleveland, Ohio).

Suitable reporter molecules or labels, which may be used, includeradionuclides, enzymes, fluorescent, chemiluminescent, or chromogenicagents as well as substrates, co-factors, inhibitors, magneticparticles, and the like.

Host cells transformed with nucleotide sequences encoding Mnk may becultured under conditions suitable for the expression and recovery ofthe protein from cell culture. The protein produced by a recombinantcell may be secreted or contained intracellularly depending on thesequence and/or the vector used. As will be understood by those of skillin the art, expression vectors containing polynucleotides which encodeMnk may be designed to contain signal sequences, which direct secretionof Mnk through a prokaryotic or eukaryotic cell membrane. Otherrecombinant constructions may be used to join sequences encoding Mnk tonucleotide sequence encoding a polypeptide domain, which will facilitatepurification of soluble proteins. Such purification facilitating domainsinclude, but are not limited to, metal chelating peptides such ashistidine-tryptophan modules that allow purification on immobilisedmetals, protein A domains that allow purification on immobilisedimmunoglobulin, and the domain utilised in the FLAG extension/affinitypurification system (Immunex Corp., Seattle, Wash.) The inclusion ofcleavable linker sequences such as those specific for Factor XA orEnterokinase (Invitrogen, San Diego, Calif.) between the purificationdomain and Mnk may be used to facilitate purification. One suchexpression vector provides for expression of a fusion protein containingMnk and a nucleic acid encoding 6 histidine residues preceding aThioredoxine or an Enterokinase cleavage site. The histidine residuesfacilitate purification on IMIAC (immobilised metal ion affinitychromatography as described in Porath, J. et al. (1992, Prot. Exp.Purif. 3: 263-281)) while the Enterokinase cleavage site provides ameans for purifying Mnk from the fusion protein. A discussion of vectorswhich contain fusion proteins is provided in Kroll, D. J. et al. (1993;DNA Cell Biol. 12:441-453). In addition to recombinant production,fragments of Mnk may be produced by direct peptide synthesis usingsolid-phase techniques (Merrifield J. (1963) J. Am. Chem. Soc.85:2149-2154). Protein synthesis may be performed using manualtechniques or by automation. Automated synthesis may be achieved, forexample, using Applied Biosystems 431 A peptide synthesiser (PerkinElmer). Various fragments of Mnk may be chemically synthesisedseparately and combined using chemical methods to produce the fulllength molecule.

Diagnostics and Therapeutics

The data disclosed in this invention show that the nucleic acids andproteins of the invention and effector molecules thereof are useful indiagnostic and therapeutic applications implicated, for example but notlimited to, in metabolic disorders like obesity, diabetes, eatingdisorders, wasting syndromes (cachexia), pancreatic dysfunctions,arteriosclerosis, coronary artery disease (CAD), and other diseases anddisorders as described above. Hence, diagnostic and therapeutic uses forthe Mnk proteins of the invention are, for example but not limited to,the following: (i) protein therapeutic, (ii) small molecule drug target,(iii) antibody target (therapeutic, diagnostic, drug targeting/cytotoxicantibody), (iv) diagnostic and/or prognostic marker, (v) gene therapy(gene delivery/gene ablation), (vi) research tools, and (vii) tissueregeneration in vitro and in vivo (regeneration for all these tissuesand cell types composing these tissues and cell types derived from thesetissues).

The nucleic acids and proteins of the invention are useful in diagnosticand therapeutic applications implicated in various diseases anddisorders described above and/or other pathologies and disorders. Forexample, but not limited to, cDNAs encoding the Mnk proteins of theinvention and particularly their human homologues may be useful in genetherapy, and the Mnk proteins of the invention and particularly theirhuman homologues may be useful when administered to a subject in needthereof. By way of non-limiting example, the compositions of the presentinvention will have efficacy for treatment of patients suffering from,for example, but not limited to, in metabolic disorders like obesity,diabetes, eating disorders, wasting syndromes (cachexia), pancreaticdysfunctions, arteriosclerosis, coronary artery disease (CAD), and otherdiseases and disorders, particularly as described above.

The nucleic acid(s) encoding the Mnk protein(s) of the invention, orfragments thereof, may further be useful in diagnostic applications,wherein the presence or amount of the nucleic acids or the proteins areto be assessed. These materials are further useful in the generation ofantibodies that bind immunospecifically to the novel substances of theinvention for use in therapeutic or diagnostic methods.

For example, in one aspect, antibodies which are specific for Mnk may beused directly as an antagonist, or indirectly as a targeting or deliverymechanism for bringing a pharmaceutical agent to cells or tissue whichexpress Mnk. The antibodies may be generated using methods that are wellknown in the art. Such antibodies may include, but are not limited to,polyclonal, monoclonal, chimerical, single chain, Fab fragments, andfragments produced by a Fab expression library. Neutralising antibodies,(i.e., those which inhibit dimer formation) are especially preferred fortherapeutic use.

For the production of antibodies, various hosts including goats,rabbits, rats, mice, humans, and others, may be immunised by injectionwith Mnk any fragment or oligopeptide thereof which has immunogenicproperties. Depending on the host species, various adjuvants may be usedto increase immunological response. Such adjuvants include, but are notlimited to, Freund's, mineral gels such as aluminium hydroxide, andsurface active substances such as lysolecithin, pluronic polyols,polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, anddinitrophenol. Among adjuvants used in human, BCG (BacilleCalmette-Guerin) and Corynebacterium parvum are especially preferable.It is preferred that the peptides, fragments, or oligopeptides used toinduce antibodies to Mnk have an amino acid sequence consisting of atleast five amino acids, and more preferably at least 10 amino acids. Itis preferable that they are identical to a portion of the amino acidsequence of the natural protein, and they may contain the entire aminoacid sequence of a small, naturally occurring molecule. Short stretchesof Mnk amino acids may be fused with those of another protein such askeyhole limpet hemocyanin and antibody produced against the chimericmolecule.

Monoclonal antibodies to Mnk may be prepared using any technique whichprovides for the production of antibody molecules by continuous celllines in culture. These include, but are not limited to, the hybridomatechnique, the human B-cell hybridoma technique, and the EBV-hybridomatechnique (Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. etal. (1985) J. Immunol. Methods 81:31-42; Cote, R. J. et al. Proc. Natl.Acad. Sci. 80:2026-2030; Cole, S. P. et al. (1984) Mol. Cell. Biol.62:109-120).

In addition, techniques developed for the production of “chimericantibodies”, the splicing of mouse antibody genes to human antibodygenes to obtain a molecule with appropriate antigen specificity andbiological activity can be used (Morrison, S. L. et al. (1984) Proc.Natl. Acad. Sci. 81:6851-6855; Neuberger, M. S. et al (1984) Nature312:604-608; Takeda, S. et al. (1985) Nature 314:452-454).Alternatively, techniques described for the production of single chainantibodies may be adapted, using methods known in the art, to produceMnk-specific single chain antibodies. Antibodies with relatedspecificity, but of distinct idiotypic composition, may be generated bychain shuffling from random combinatorial immunoglobulin libraries(Burton, D. R. (1991) Proc. Natl. Acad. Sci. 88:11120-3). Antibodies mayalso be produced by inducing in vivo production in the lymphocytepopulation or by screening recombinant immunoglobulin libraries orpanels of highly specific binding reagents as disclosed in theliterature (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci.86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

Antibody fragments, which contain specific binding sites for Mnk, mayalso be generated. For example, such fragments include, but are notlimited to proteolytic fragments, e.g. the F(ab′)₂ fragments which canbe produced by Pepsin digestion of the antibody molecule and the Fabfragments which can be generated by reducing the disulfide bridges ofF(ab′)₂ fragments. Alternatively, recombinant fragments may begenerated. For example, Fab expression libraries may be constructed toallow rapid and easy identification of monoclonal Fab fragments with thedesired specificity (Huse, W. D. et al. (1989) Science 254:1275-1281).

Various immunoassays may be used for screening to identify antibodieshaving the desired specificity. Numerous protocols for competitivebinding and immunoradiometric assays using either polyclonal ormonoclonal antibodies with established specificities are well known inthe art. Such immunoassays typically involve the measurement of complexformation between Mnk and its specific antibody. A two-site,monoclonal-based immunoassay utilising monoclonal antibodies reactive totwo non-interfering Mnk epitopes is preferred, but a competitive bindingassay may also be employed (Maddox, supra).

In another embodiment of the invention, the Mnk polynucleotides or anyfragment thereof, or nucleic acid effector molecules, aptamers,anti-sense molecules, ribozymes or RNAi molecules, may be used fortherapeutic purposes. In one aspect, aptamers, i.e. nucleic acidmolecules, which are capable of binding to a Mnk protein and modulatingits activity, may be generated by a screening and selection procedureinvolving the use of combinational nucleic acid libraries.

In a further aspect, antisense molecules to the polynucleotide encodingMnk may be used in situations in which it would be desirable to blockthe transcription of the mRNA. In particular, cells may be transformedwith sequences complementary to polynucleotides encoding Mnk. Thus,antisense molecules may be used to modulate Mnk activity, or to achieveregulation of gene function. Such technology is now well known in theart, and sense or antisense oligomers or larger fragments, can bedesigned from various locations along the coding or control regions ofsequences encoding Mnk. Expression vectors derived from retroviruses,adenovirus, herpes or vaccinia viruses, or from various bacterialplasmids may be used for delivery of nucleotide sequences to thetargeted organ, tissue or cell population. Methods, which are well knownto those skilled in the art, can be used to construct recombinantvectors, which will express antisense molecules complementary to thepolynucleotides of the gene encoding Mnk. These techniques are describedboth in Sambrook et al. (supra) and in Ausubel et al. supra). Genesencoding Mnk can be turned off by transforming a cell or tissue withexpression vectors which express high levels of polynucleotide orfragment thereof which encodes Mnk. Such constructs may be used tointroduce untranslatable sense or antisense sequences into a cell. Evenin the absence of integration into the DNA, such vectors may continue totranscribe RNA molecules until they are disabled by endogenousnucleases. Transient expression may last for a month or more with anon-replicating vector and even longer if appropriate replicationelements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained bydesigning antisense molecules, e.g. DNA, RNA, or nucleic acid analoguessuch as PNA, to the control regions of the gene encoding Mnk, i.e., thepromoters, enhancers, and introns. Oligonucleotides derived from thetranscription initiation site, e.g., between positions −10 and +10 fromthe start site, are preferred. Similarly, inhibition can be achievedusing “triple helix” base-pairing methodology. Triple helix pairing isuseful because it cause inhibition of the ability of the double helix toopen sufficiently for the binding of polymerases, transcription factors,or regulatory molecules. Recent therapeutic advances using triplex DNAhave been described in the literature (Gee, J. E. et al. (1994) In;Huber, B. E. and B. I. Carr, Molecular and Immunologic Approaches,Futura Publishing Co., Mt. Kisco, N.Y.). The antisense molecules mayalso be designed to block translation of mRNA by preventing thetranscript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyse thespecific cleavage of RNA. The mechanism of ribozyme action involvessequence-specific hybridisation of the ribozyme molecule tocomplementary target RNA, followed by endonucleolytic cleavage.Examples, which may be used, include engineered hammerhead motifribozyme molecules that can be specifically and efficiently catalyseendonucleolytic cleavage of sequences encoding Mnk. Specific ribozymecleavage sites within any potential RNA target are initially identifiedby scanning the target molecule for ribozyme cleavage sites whichinclude the following sequences: GUA, GUU, and GUC. Once identified,short RNA sequences of between 15 and 20 ribonucleotides correspondingto the region of the target gene containing the cleavage site may beevaluated for secondary structural features which may render theoligonucleotide inoperable. The suitability of candidate targets mayalso be evaluated by testing accessibility to hybridisation withcomplementary oligonucleotides using ribonuclease protection assays.

Effector molecules, e.g. antisense molecules and ribozymes of theinvention may be prepared by any method known in the art for thesynthesis of nucleic acid molecules. These include techniques forchemically synthesising oligonucleotides such as solid phasephosphoramidite chemical synthesis. Alternatively, RNA molecules may begenerated by in vitro and in vivo transcription of DNA sequencesencoding Mnk. Such DNA sequences may be incorporated into a variety ofvectors with suitable RNA polymerase promoters such as T7 or SP6.Alternatively, these cDNA constructs that synthesise antisense RNAconstitutively or inducibly can be introduced into cell lines, cells, ortissues. RNA molecules may be modified to increase intracellularstability and half-life. Possible modifications include, but are notlimited to, the addition of flanking sequences at the 5′ and/or 3′ endsof the molecule or the use of phosphorothioate or 2′ O-methyl ratherthan phosphodiesterase linkages within the backbone of the molecule.This concept is inherent in the production of PNAs and can be extendedin all of these molecules by the inclusion of non-traditional bases suchas inosine, queosine, and wybutosine, as well as acetyl-, methyl-,thio-, and similarly modified forms of adenine, cytidine, guanine,thymine, and uridine which are not as easily recognised by endogenousendonucleases.

The activity of Mnk proteins can be assayed for example by in vitrokinase assays, as described by Tschopp et al., 2000, supra or any othersuitable assay principle as described below. As inhibitor of Mnk in thisassay, a staurosporine derivative such as CGP57380 or CGP052088 can beused, as described by Tschopp et al., 2000, supra or Knauf et al., 2001,supra. As negative control, the compound CGP52428 which is inactiveagainst Mnk, but displays a similar cytotoxicity as CGP052088, or anyother chemical entities with kinase inhibitory activity with exceptionof activity against Mnk may be used. Moreover, derivatives of CGP57380can be assayed for activity against Mnk and are substances for thetreatment, prophylaxis, and diagnosis of metabolic diseases as mentionedabove. Derivatives of CGP57380 could for example be generated bymodification through conventional chemical, physical and biochemicalmeans, and may be used to produce combinatorial libraries. They may besubjected to directed or random chemical modifications, such asacylation, alkylation, esterification, amidification, etc. to producestructural analogs.

Further, the invention relates to the use of Mnk kinase inhibitors oractivators for the treatment, prophylaxis or diagnosis of metabolicdiseases as mentioned above. Preferably, but not exclusively, the Mnkkinase inhibitors are staurosporine or pyrazole derivatives. Examples ofpyrazole derivatives are described in EP-A-0 819 129 which is hereinincorporated by reference. Since CGP57380 is not cytotoxic up to 30 μM,this substance may be preferably used to inhibit kinase activity,preferably Mnk2, and used as substance for the treatment, prophylaxis,and diagnosis of metabolic diseases as mentioned above.

Many methods for introducing vectors into cells or tissues are availableand equally suitable for use in vivo, in vitro, and ex vivo. For ex vivotherapy, vectors may be introduced into stem cells taken from thepatient and clonally propagated for autologous transplant back into thatsame patient. Delivery by transfection and by liposome injections may beachieved using methods, which are well known in the art. Any of thetherapeutic methods described above may be applied to any suitablesubject including, for example, mammals such as dogs, cats, cows,horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administrationof a pharmaceutical composition, in conjunction with a pharmaceuticallyacceptable carrier, for any of the therapeutic effects discussed above.Such pharmaceutical compositions may consist of Mnk, antibodies to Mnk,mimetics, agonists, antagonists, or inhibitors of Mnk. The compositionsmay be administered alone or in combination with at least one otheragent, such as stabilising compound, which may be administered in anysterile, biocompatible pharmaceutical carrier, including, but notlimited to, saline, buffered saline, dextrose, and water. Thecompositions may be administered to a patient alone, or in combinationwith other agents, drugs or hormones. The pharmaceutical compositionsutilised in this invention may be administered by any number of routesincluding, but not limited to, oral, intravenous, intramuscular,intra-arterial, intramedullary, intrathecal, intraventricular,transdermal, subcutaneous, intraperitoneal, intranasal, enteral,topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositionsmay contain suitable pharmaceutically-acceptable carriers comprisingexcipients and auxiliaries, which facilitate processing of the activecompounds into preparations which, can be used pharmaceutically. Furtherdetails on techniques for formulation and administration may be found inthe latest edition of Remington's Pharmaceutical Sciences (MaackPublishing Co., Easton, Pa.). Pharmaceutical compositions for oraladministration can be formulated using pharmaceutically acceptablecarriers well known in the art in dosages suitable for oraladministration. Such carriers enable the pharmaceutical compositions tobe formulated as tablets, pills, dragees, capsules, liquids, gels,syrups, slurries, suspensions, and the like, for ingestion by thepatient.

The pharmaceutical compositions of the present invention may bemanufactured in a manner that is known in the art, e.g., by means ofconventional mixing, dissolving, granulating, dragee-making, levigating,emulsifying, encapsulating, entrapping, or lyophilising processes. Thepharmaceutical composition may be provided as a salt and can be formedwith many acids, including but not limited to, hydrochloric, sulphuric,acetic, lactic, tartaric, malic, succinic, etc. After pharmaceuticalcompositions have been prepared, they can be placed in an appropriatecontainer and labelled for treatment of an indicated condition. Foradministration of Mnk, such labelling would include amount, frequency,and method of administration.

Pharmaceutical compositions suitable for use in the invention includecompositions wherein the active ingredients are contained in aneffective amount to achieve the intended purpose. The determination ofan effective dose is well within the capability of those skilled in theart. For any compounds, the therapeutically effective does can beestimated initially either in cell culture assays, e.g., of preadipocytecell lines, or in animal models, usually mice, rabbits, dogs, or pigs.The animal model may also be used to determine the appropriateconcentration range and route of administration. Such information canthen be used to determine useful doses and routes for administration inhumans. A therapeutically effective dose refers to that amount of activeingredient, for example Mnk fragments thereof, antibodies of Mnk, totreat a specific condition. Therapeutic efficacy and toxicity may bedetermined by standard pharmaceutical procedures in cell cultures orexperimental animals, e.g., ED50 (the dose therapeutically effective in50% of the population) and LD50 (the dose lethal to 50% of thepopulation). The dose ratio between therapeutic and toxic effects is thetherapeutic index, and it can be expressed as the ratio, LD50/ED50.Pharmaceutical compositions, which exhibit large therapeutic indices,are preferred. The data obtained from cell culture assays and animalstudies is used in formulating a range of dosage for human use. Thedosage contained in such compositions is preferably within a range ofcirculating concentrations that include the ED50 with little or notoxicity. The dosage varies within this range depending upon the dosagefrom employed, sensitivity of the patient, and the route ofadministration. The exact dosage will be determined by the practitioner,in light of factors related to the subject that requires treatment.Dosage and administration are adjusted to provide sufficient levels ofthe active moiety or to maintain the desired effect. Factors, which maybe taken into account, include the severity of the disease state,general health of the subject, age, weight, and gender of the subject,diet, time and frequency of administration, drug combination(s),reaction sensitivities, and tolerance/response to therapy. Long-actingpharmaceutical compositions may be administered every 3 to 4 days, everyweek, or once every two weeks depending on half-life and clearance rateof the particular formulation. Normal dosage amounts may vary from 0.1to 100,000 micrograms, up to a total dose of about 1 g, depending uponthe route of administration. Guidance as to particular dosages andmethods of delivery is provided in the literature and generallyavailable to practitioners in the art. Those skilled in the art employdifferent formulations for nucleotides than for proteins or theirinhibitors. Similarly, delivery of polynucleotides or polypeptides willbe specific to particular cells, conditions, locations, etc.

In another embodiment, antibodies which specifically bind Mnk may beused for the diagnosis of conditions or diseases characterised by orassociated with over- or underexpression of Mnk, or in assays to monitorpatients being treated with Mnk, agonists, antagonists or inhibitors.The antibodies useful for diagnostic purposes may be prepared in thesame manner as those described above for therapeutics. Diagnostic assaysfor Mnk include methods, which utilise the antibody and a label todetect Mnk in human body fluids or extracts of cells or tissues. Theantibodies may be used with or without modification, and may be labelledby joining them, either covalently or non-covalently, with a reportermolecule. A wide variety of reporter molecules, which are known in theart may be used several of which are described above.

A variety of protocols including ELISA, RIA, and FACS for measuring Mnkare known in the art and provide a basis for diagnosing altered orabnormal levels of Mnk expression. Normal or standard values for Mnkexpression are established by combining body fluids or cell extractstaken from normal mammalian subjects, preferably human, with antibody toMnk under conditions suitable for complex formation. The amount ofstandard complex formation may be quantified by various methods, butpreferably by photometric, means. Quantities of Mnk expressed in controland disease samples e.g. from biopsied tissues are compared with thestandard values. Deviation between standard and subject valuesestablishes the parameters for diagnosing disease. Analysis of Mnkexpression can also be performed by determination of Mnk activity inassay formats well known in the art and described in more detail below.

In another embodiment of the invention, the polynucleotides specific forMnk may be used for diagnostic purposes. The polynucleotides, which maybe used, include oligonucleotide sequences, antisense RNA and DNAmolecules, and PNAs. The polynucleotides may be used to detect andquantitate gene expression in biopsied tissues in which expression ofMnk may be correlated with disease. The diagnostic assay may be used todistinguish between absence, presence, and excess expression of Mnk, andto monitor regulation of Mnk levels during therapeutic intervention.

In one aspect, hybridisation with PCR probes which are capable ofdetecting polynucleotide sequences, including genomic sequences,encoding Mnk and/or closely related molecules, may be used to identifynucleic acid sequences which encode Mnk. The specificity of the probe,whether it is made from a highly specific region, e.g., uniquenucleotides in the 5′ regulatory region, or a less specific region,e.g., especially in the 3′ coding region, and the stringency of thehybridisation or amplification (maximal, high, intermediate, or low)will determine whether the probe identifies only naturally occurringsequences encoding Mnk, alleles, or related sequences. Probes may alsobe used for the detection of related sequences, and should preferablycontain at least 50% of the nucleotides from any of the Mnk encodingsequences. The hybridisation probes of the subject invention may be DNAor RNA and derived from the nucleotide sequence of AF237775,NM_(—)017572.1, NM_(—)003684.2, or AB000409.1 or from a genomic sequenceincluding promoter, enhancer elements, and introns of the naturallyoccurring Mnk. Means for producing specific hybridisation probes forDNAs encoding Mnk include the cloning of nucleic acid sequences encodingMnk derivatives into vectors for the production of mRNA probes. Suchvectors are known in the art, commercially available, and may be used tosynthesise RNA probes in vitro by means of the addition of theappropriate RNA polymerases and the appropriate labelled nucleotides.Hybridisation probes may be labelled by a variety of reporter groups,for example, radionuclides such as ³²P or ³⁵S, or enzymatic labels, suchas alkaline phosphatase coupled to the probe via avidin/biotin couplingsystems, and the like. Polynucleotide sequences encoding Mnk may be usedfor the diagnosis of conditions or diseases, which are associated withexpression of Mnk. Examples of such conditions or diseases include, butare not limited to, pancreatic diseases and disorders, includingdiabetes.

Polynucleotide sequences encoding Mnk may also be used to monitor theprogress of patients receiving treatment for pancreatic diseases anddisorders, including diabetes. The polynucleotide sequences encoding Mnkmay be used in Southern or Northern analysis, dot blot, or othermembrane-based technologies; in PCR technologies; or in dip stick, pin,ELISA or chip assays utilising fluids or tissues from patient biopsiesto detect altered Mnk expression. Such qualitative or quantitativemethods are well known in the art.

In a particular aspect, the nucleotide sequences encoding Mnk may beuseful in assays that detect activation or induction of variousmetabolic diseases and disorders, including obesity, diabetes, eatingdisorders, wasting syndromes (cachexia), pancreatic dysfunctions,arteriosclerosis, coronary artery disease (CAD), disorders related toROS production, and neurodegenerative diseases. The nucleotide sequencesencoding Mnk may be labelled by standard methods, and added to a fluidor tissue sample from a patient under conditions suitable for theformation of hybridisation complexes. After a suitable incubationperiod, the sample is washed and the signal is quantitated and comparedwith a standard value. The presence of altered levels of nucleotidesequences encoding Mnk in the sample compared to a control sampleindicates the presence of the associated disease. Such assays may alsobe used to evaluate the efficacy of a particular therapeutic treatmentregimen in animal studies, in clinical trials, or in monitoring thetreatment of an individual patient.

In order to provide a basis for the diagnosis of disease associated withexpression of Mnk, a normal or standard profile for expression isestablished. This may be accomplished by combining body fluids or cellextracts taken from normal subjects, either animal or human, with asequence, or a fragment thereof, which encodes Mnk, under conditionssuitable for hybridisation or amplification. Standard hybridisation maybe quantified by comparing the values obtained from normal subjects withthose from an experiment where a known amount of a substantiallypurified polynucleotide is used. Standard values obtained from normalsamples may be compared with values obtained from samples from patientswho are symptomatic for disease. Deviation between standard and subjectvalues is used to establish the presence of disease. Once disease isestablished and a treatment protocol is initiated, hybridisation assaysmay be repeated on a regular basis to evaluate whether the level ofexpression in the patient begins to approximate that, which is observedin the normal patient. The results obtained from successive assays maybe used to show the efficacy of treatment over a period ranging fromseveral days to months.

With respect to metabolic diseases and disorders, including obesity,diabetes, eating disorders, wasting syndromes (cachexia), pancreaticdysfunctions, arteriosclerosis, coronary artery disease (CAD), disordersrelated to ROS production, and neurodegenerative diseases presence of arelatively high amount of transcript in biopsied tissue from anindividual may indicate a predisposition for the development of thedisease, or may provide a means for detecting the disease prior to theappearance of actual clinical symptoms. A more definitive diagnosis ofthis type may allow health professionals to employ preventative measuresor aggressive treatment earlier thereby preventing the development orfurther progression of the pancreatic diseases and disorders. Additionaldiagnostic uses for oligonucleotides designed from the sequencesencoding Mnk may involve the use of PCR. Such oligomers may bechemically synthesised, generated enzymatically, or produced from arecombinant source. Oligomers will preferably consist of two nucleotidesequences, one with sense orientation (5′.fwdarw.3′) and another withantisense (3′.rarw.5′), employed under optimised conditions foridentification of a specific gene or condition. The same two oligomers,nested sets of oligomers, or even a degenerate pool of oligomers may beemployed under less stringent conditions for detection and/orquantification of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of Mnkinclude radiolabelling or biotinylating nucleotides, coamplification ofa control nucleic acid, and standard curves onto which the experimentalresults are interpolated (Melby, P. C. et al. (1993) J. Immunol.Methods, 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem.212:229-236). The speed of quantification of multiple samples may beaccelerated by running the assay in an ELISA format where the oligomerof interest is presented in various dilutions and a spectrophotometricor colorimetric response gives rapid quantification.

In another embodiment of the invention, the nucleic acid Mnk sequencesmay also be used to generate hybridisation probes, which are useful formapping the naturally occurring genomic sequence. The sequences may bemapped to a particular chromosome or to a specific region of thechromosome using well known techniques. Such techniques include FISH,FAGS, or artificial chromosome constructions, such as yeast artificialchromosomes, bacterial artificial chromosomes, bacterial P1constructions or single chromosome cDNA libraries as reviewed in Price,C. M. (1993) Blood Rev. 7:127-134, and Trask, B. J. (1991) Trends Genet.7:149-154. FISH (as described in Verma et al. (1988) Human Chromosomes:A Manual of Basic Techniques, Pergamon Press, New York, N.Y.) may becorrelated with other physical chromosome mapping techniques and geneticmap data. Examples of genetic map data can be found in the 1994 GenomeIssue of Science (265:1981f). Correlation between the location of thegene encoding Mnk on a physical chromosomal map and a specific disease,or predisposition to a specific disease, may help to delimit the regionof DNA associated with that genetic disease.

The nucleotide sequences of the subject invention may be used to detectdifferences in gene sequences between normal, carrier or affectedindividuals. In situ hybridization of chromosomal preparations andphysical mapping techniques such as linkage analysis using establishedchromosomal markers may be used for extending genetic maps. Often theplacement of a gene on the chromosome of another mammalian species, suchas mouse, may reveal associated markers even if the number or arm of aparticular human chromosome is not known. New sequences can be assignedto chromosomal arms or parts thereof, by physical mapping. This providesvaluable information to investigators searching for disease genes usingpositional cloning or other gene discovery techniques. Once the diseaseor syndrome has been crudely localized by genetic linkage to aparticular genomic region, for example, AT to 11q22-23 (Gatti, R. A. etal. (1988) Nature 336:577-580), any sequences mapping to that area mayrepresent associated or regulatory genes for further investigation. Thenucleotide sequences of the subject invention may also be used to detectdifferences in the chromosomal location due to translocation, inversion,etc. among normal, carrier or affected individuals.

In another embodiment of the invention, the proteins of the invention,its catalytic or immunogenic fragments or oligopeptides thereof, an invitro model, a genetically altered cell or animal, can be used forscreening libraries of compounds in any of a variety of drug screeningtechniques. One can identify effectors, e.g. receptors, enzymes,proteins, peptides, ligands or substrates that bind to, modulate ormimic the action of one or more of the proteins of the invention. Theprotein or fragment thereof employed in such screening may be free insolution, affixed to a solid support, borne on a cell surface, orlocated intracellularly. The formation of binding complexes, between theproteins of the invention and the agent tested, may be measured. Agentscould also, either directly or indirectly, influence the activity of theproteins of the invention. Target mechanisms can for example include akinase activity, particularly the phosphorylation of proteins orpeptides, most preferably, but not limited to serine and threonineresidues. Another target mechanism could include the regulation of Mnkfunction by posttranslational modifications such as phosphorylation,dephosphorylation, acetylation, alkylation, ubiquitination, proteolyticprocessing subcellular localization or degradation. Yet another targetmechanism could include the interaction of Mnk with protein bindingpartners such as, but not limited to, phospholipase A, estrogenreceptors, kinases or translation factors. Of particular interest arescreening assays for agents that have a low toxicity for mammaliancells. The term “agent” as used herein describes any molecule, e.g.protein or pharmaceutical, with the capability of altering or mimickingthe physiological function of one or more of the proteins of theinvention. Candidate agents encompass numerous chemical classes, thoughtypically they are organic molecules, preferably small organic compoundshaving a molecular weight of more than 50 and less than about 2,500Daltons. Candidate agents comprise functional groups necessary forstructural interaction with proteins, particularly hydrogen bonding, andtypically include at least an amine, carbonyl, hydroxyl or carboxylgroup, preferably at least two of the functional chemical groups. Thecandidate agents often comprise carbocyclic or heterocyclic structuresand/or aromatic or polyaromatic structures substituted with one or moreof the above functional groups.

Candidate agents are also found among biomolecules including peptides,saccharides, fatty acids, steroids, purines, pyrimidines, nucleic acidsand derivatives, structural analogs or combinations thereof. Candidateagents are obtained from a wide variety of sources including librariesof synthetic or natural compounds. For example, numerous means areavailable for random and directed synthesis of a wide variety of organiccompounds and biomolecules, including expression of randomizedoligonucleotides and oligopeptides. Alternatively, libraries of naturalcompounds in the form of bacterial, fungal, plant and animal extractsare available or readily produced. Additionally, natural orsynthetically produced libraries and compounds are readily modifiedthrough conventional chemical, physical and biochemical means, and maybe used to produce combinatorial libraries. Known pharmacological agentsmay be subjected to directed or random chemical modifications, such asacylation, alkylation, esterification, amidification, etc. to producestructural analogs. Where the screening assay is a binding assay, one ormore of the molecules may be joined to a label, where the label candirectly or indirectly provide a detectable signal.

Another technique for drug screening, which may be used, provides forhigh throughput screening of compounds having suitable binding affinityto the protein of interest as described in published PCT applicationWO84/03564. In this method, as applied to the proteins of the inventionlarge numbers of different small test compounds, e.g. aptamers,peptides, low-molecular weight compounds etc., are provided orsynthesized on a solid substrate, such as plastic pins or some othersurface. The test compounds are reacted with the proteins or fragmentsthereof, and washed. Bound proteins are then detected by methods wellknown in the art. Purified proteins can also be coated directly ontoplates for use in the aforementioned drug screening techniques.Alternatively, non-neutralizing antibodies can be used to capture thepeptide and immobilize it on a solid support. In another embodiment, onemay use competitive drug screening assays in which neutralizingantibodies capable of binding the protein specifically compete with atest compound for binding the protein. In this manner, the antibodiescan be used to detect the presence of any peptide, which shares one ormore antigenic determinants with the protein.

Candidate agents may also be found in kinase assays where a kinasesubstrate such as a protein or a peptide, which may or may not includemodifications as further described below, or others are phosphorylatedby the proteins or protein fragments of the invention. A therapeuticcandidate agent may be identified by its ability to increase or decreasethe enzymatic activity of the proteins of the invention. The kinaseactivity may be detected by change of the chemical, physical orimmunological properties of the substrate due to phosphorylation.

One example could be the transfer of radioisotopically labelledphosphate groups from an appropriate donor molecule to the kinasesubstrate catalyzed by the polypeptides of the invention. Thephosphorylation of the substrate may be followed by detection of thesubstrates autoradiography with techniques well known in the art.

Yet in another example, the change of mass of the substrate due to itsphosphorylation may be detected by mass spectrometry techniques.

One could also detect the phosphorylation status of a substrate with areagent discriminating between the phosphorylated and unphosphorylatedstatus of the substrate. Such a reagent may act by having differentaffinities for the phosphorylated and unphosphorylated forms of thesubstrate or by having specific affinity for phosphate groups. Such areagent could be, but is not limited to, an antibody or antibodyderivative, a recombinant antibody-like structure, a protein, a nucleicacid, a molecule containing a complexed metal ion, an anion exchangechromatography matrix, an affinity chromatography matrix or any othermolecule with phosphorylation dependent selectivity towards thesubstrate.

Such a reagent could be employed to detect the kinase substrate, whichis immobilized on a solid support during or after an enzymatic reaction.If the reagent is an antibody, its binding to the substrate could bedetected by a variety of techniques as they are described in Harlow andLane, 1998, Antibodies, CSH Lab Press, NY. If the reagent molecule isnot an antibody, it may be detected by virtue of its chemical, physicalor immunological properties, being endogenously associated with it orengineered to it.

Yet in another example the kinase substrate may have features, designedor endogenous, to facilitate its binding or detection in order togenerate a signal that is suitable for the analysis of the substratesphosphorylation status. These features may be, but are not limited to, abiotin molecule or derivative thereof, a glutathione-S-transferasemoiety, a moiety of six or more consecutive histidine residues, an aminoacid sequence or hapten to function as an epitope tag, a fluorochrome,an enzyme or enzyme fragment. The kinase substrate may be linked tothese or other features with a molecular spacer arm to avoid sterichindrance.

In one example the kinase substrate may be labelled with a fluorophore.The binding of the reagent to the labelled substrate in solution may befollowed by the technique of fluorescence polarization as it isdescribed in the literature (see, for example, Deshpande, S. et al.(1999) Prog. Biomed. Optics (SPIE) 3603:261; Parker, G. J. et al. (2000)J. Biomol. Screen. 5:77-88; Wu, P. et al. (1997) Anal. Biochem.249:29-36). In a variation of this example, a fluorescent tracermolecule may compete with the substrate for the analyte to detect kinaseactivity by a technique which is known to those skilled in the art asindirect fluorescence polarization.

The nucleic acids encoding the proteins of the invention can be used togenerate transgenic cell lines and animals. These transgenic animals areuseful in the study of the function and regulation of the proteins ofthe invention in vivo. Transgenic animals, particularly mammaliantransgenic animals, can serve as a model system for the investigation ofmany developmental and cellular processes common to humans. Transgenicanimals may be made through homologous recombination in embryonic stemcells, where the normal locus of the gene encoding the protein of theinvention is mutated. Alternatively, a nucleic acid construct encodingthe protein is injected into oocytes and is randomly integrated into thegenome. One may also express the genes of the invention or variantsthereof in tissues where they are not normally expressed or at abnormaltimes of development. Furthermore, variants of the genes of theinvention like specific constructs expressing anti-sense molecules orexpression of dominant negative mutations, which will block or alter theexpression of the proteins of the invention may be randomly integratedinto the genome. A detectable marker, such as lac Z or luciferase may beintroduced into the locus of the genes of the invention, whereupregulation of expression of the genes of the invention will result inan easily detectable change in phenotype. Vectors for stable integrationinclude plasmids, retroviruses and other animal viruses, yeastartificial chromosomes (YACs), and the like. DNA constructs forhomologous recombination will contain at least portions of the genes ofthe invention with the desired genetic modification, and will includeregions of homology to the target locus. Conveniently, markers forpositive and negative selection are included. DNA constructs for randomintegration do not need to contain regions of homology to mediaterecombination. DNA constructs for random integration will consist of thenucleic acids encoding the proteins of the invention, a regulatoryelement (promoter), an intron and a poly-adenylation signal. Methods forgenerating cells having targeted gene modifications through homologousrecombination are known in the field. For embryonic stem (ES) cells, anES cell line may be employed, or embryonic cells may be obtained freshlyfrom a host, e.g. mouse, rat, guinea pig, etc. Such cells are grown onan appropriate fibroblast-feeder layer and are grown in the presence ofleukemia inhibiting factor (LIF). ES or embryonic cells may betransfected and can then be used to produce transgenic animals. Aftertransfection, the ES cells are plated onto a feeder layer in anappropriate medium. Cells containing the construct may be selected byemploying a selection medium. After sufficient time for colonies togrow, they are picked and analyzed for the occurrence of homologousrecombination. Colonies that are positive may then be used for embryomanipulation and morula aggregation. Briefly, morulae are obtained from4 to 6 week old superovulated females, the Zona Pellucida is removed andthe morulae are put into small depressions of a tissue culture dish. TheES cells are trypsinized, and the modified cells are placed into thedepression closely to the morulae. On the following day the aggregatesare transfered into the uterine horns of pseudopregnant females. Femalesare then allowed to go to term. Chimeric offsprings can be readilydetected by a change in coat color and are subsequently screened for thetransmission of the mutation into the next generation (F1-generation).Offspring of the F1-generation are screened for the presence of themodified gene and males and females having the modification are mated toproduce homozygous progeny. If the gene alterations cause lethality atsome point in development, tissues or organs can be maintained asallogenic or congenic grafts or transplants, or in vitro culture. Thetransgenic 3o animals may be any non-human mammal, such as laboratoryanimal, domestic animals, etc., for example, mouse, rat, guinea pig,sheep, cow, pig, and others. The transgenic animals may be used infunctional studies, drug screening, and other applications and areuseful in the study of the function and regulation of the proteins ofthe invention in vivo.

Finally, the invention also relates to a kit comprising at least one of

-   (a) a Mnk2 (Mnk2a or Mnk2b) or Mnk1 nucleic acid molecule or a    fragment thereof;-   (b) a vector comprising the nucleic acid of (a);-   (c) a host cell comprising the nucleic acid of (a) or the vector of    (b);-   (d) a polypeptide encoded by the nucleic acid of (a);-   (e) a fusion polypeptide encoded by the nucleic acid of (a);-   (f) an antibody, an aptamer or another receptor against the nucleic    acid of (a) or the polypeptide of (d) or (e) and-   (g) an anti-sense oligonucleotide of the nucleic acid of (a).

The kit may be used for diagnostic or therapeutic purposes or forscreening applications as described above. The kit may further containuser instructions.

The Figures show:

FIG. 1 shows the increase of triglyceride content of EP(3)3333 andEP(3)3576 male flies caused by homozygous viable integration of theP-vector (in comparison to EP-control males). Shown is the ratio of thetriglyceride to protein content of the mutants in percent(%)).

FIG. 2 shows the molecular organisation of the mutated LK6 gene locus.The dotted black line represents the position of the cDNA (from position7544500 to 7559500 on chromosome 3R) that includes the integration sitesof EP(3)3333 and EP(3)3576. Transcribed DNA sequences (ESTs) andpredicted exons are shown as bars in the lower two lines. Predictedexons of gene CG17342 (GadFly, Lk6) are shown as dark grey bars andintrons as light grey bars. Lk6 encodes for a gene that is predicted byGadFly sequence analysis programs as Gadfly Accession Number CG17342.

FIGS. 3A and 3B show the comparison of Mnk proteins.

FIG. 3A shows the comparison (CLUSTAL×1.8) of Mnk proteins fromdifferent species, hXP 030637 refers to human Mnk2 (identical to GenbankAccession No. AF237775), hXP_(—)001600 refers to human Mnk1 (identicalto Genbank Accession No. AB000409.1), and AAB 18789 refers to theprotein encoded by Drosophila Lk6 gene with GadFly Accession No.CG17342. Gaps in the alignment are represented as -.

FIG. 3B shows the comparison (CLUSTAL W 1.82) of human Mnk2 proteins.Genbank Accession Number XM 030637.3 is identical to Genbank AccessionNumber AF237775, and Genbank Accession Number NM_(—)017572.1 shows adifferent variant of the human Mnk2 protein.

FIG. 3C shows the comparison (CLUSTAL W 1.82) of human Mnk1 proteins.Genbank Accession Number XM 001600.2 is identical to Genbank AccessionNumber AB000409.1, and Genbank Accession Number NM003684.2 shows adifferent variant of the Mnk1 protein.

FIG. 3D. Nucleic acid sequence of human MAP kinase-interacting kinase(Mnk) 2a (SEQ ID NO: 1; GenBank Accession Number AF237775, identical toGenBank Accession Number XM_(—)030637)

FIG. 3E. Amino Acid sequence of human MAP kinase-interacting kinase(Mnk) 2a (SEQ ID NO: 2; GenBank Accession Number AF237775, identical toGenBank Accession Number XM_(—)030637)

FIG. 3F. Nucleic acid sequence of human MAP kinase-interacting kinase(Mnk) 2b (SEQ ID NO: 3; GenBank Accession Number AF237776 orNM_(—)017572)

FIG. 3G. Amino Acid sequence of human MAP kinase-interacting kinase(Mnk) 2b (SEQ ID NO: 4; GenBank Accession Number AF237776 orNM_(—)017572)

FIG. 3H. Nucleic acid sequence of human MAP kinase-interacting kinase(Mnk) 1 (SEQ ID NO: 5; GenBank Accession NumberAB000409 or NM_(—)003684or XM_(—)001600)

FIG. 3I. Amino Acid sequence of human MAP kinase-interacting kinase(Mnk) 1 (SEQ ID NO: 6; GenBank Accession NumberAB000409 or NM_(—)003684or XM_(—)001600)

FIG. 4 shows the eye phenotype induced by overexpression of anuncoupling protein (dUCPy) that was used to discover factors modulatinguncoupling protein activity. In the fly shown in the left part of thepicture, dUCPy is expressed at normal levels. In the fly shown in theright part of the photograph, dUCPy is overexpressed, and the eye isreduced.

FIGS. 5A and 58 show the expression of the Mnk2 gene.

FIG. 5A shows the real-time PCR analysis of Mnk2 in wildtype mousetissues

FIG. 5B shows the expression of mouse Mnk2 gene in fasted and obese(ob/ob) mice

FIG. 5C shows the expression of mouse Mnk2 gene in fasted and obese mice

FIG. 5D shows the real-time PCR mediated comparison of Mnk2 expressionduring differentiation of mammalian fibroblast (3T3-L1) cells frompre-adipocytes to mature adipocytes

FIG. 5E shows real-time PCR mediated comparison of Mnk2 expressionduring the differentiation of mammalian fibroblast 3T3-F442A cells frompreadipocytes to mature adipocytes

FIG. 5F shows real-time PCR mediated comparison of Mnk2 expressionduring the differentiation of mammalian fibroblast TA 1 cells frompreadipocytes to mature adipocytes

FIGS. 6A and 6B show the expression of the mouse Mnk1 gene.

FIG. 6A shows the real-time PCR analysis of Mnk1 in wildtype mousetissues

FIG. 6B shows the real-time PCR mediated comparison of Mnk1 expressionin different mouse models

FIG. 6C shows the real-time PCR mediated comparison of Mnk1 expressionduring differentiation of mammalian fibroblast 3T3-L1 cells frompre-adipocytes to mature adipocytes

FIG. 6D shows real-time PCR mediated comparison of Mnk1 expressionduring the differentiation of mammalian fibroblast 3T3-F442A cells frompreadipocytes to mature adipocytes

FIG. 6E shows real-time PCR mediated comparison of Mnk1 expressionduring the differentiation of mammalian fibroblast TA 1 cells frompreadipocytes to mature adipocytes

FIGS. 7A and 7B show the UCPy sequences

FIG. 7A shows the nucleic acid sequence encoding the Drosophila UCPyprotein (SEQ ID NO. 7). The open reading frame is underlined.

FIG. 7B shows the amino acid sequence encoding the Drosophila UCPyprotein (SEQ ID NO. 8).

FIGS. 8A and 9B: In vitro assays for the determination of triglyceridestorage, synthesis and transport.

FIG. 8A shows reduction in cellular triglyceride levels (μg/mg protein)in cells over expressing Mnk2 compared to control cells. All sampleswere analysed in duplicates (s1; sample 1, s2; sample 2). TheY-axisshows cellular triglyceride levels (μg/mg protein) and the X-axis showsdays of cell differentiation.

FIG. 8B shows reduction in insulin stimulated lipid synthesis (dpm/mgprotein) in cells over expressing Mnk2 compared to control cells. Allsamples were analysed in duplicates (s1; sample 1, s2; sample 2). CB;cytochalasin B, illustrates the background synthesis in 3T3L1, 0;represents the baseline or un-stimulated glucose transport and hencebasal lipid synthesis in the cells, while Ins; insulin shows thestimulated glucose transport and the consequent synthesis of glucose tolipid in 3T3L1 cells. The Y-axis displays disintegrations per minutes/mgprotein (dpm/mg protein) and the X-axis denotes the aforementionedproteins.

FIG. 8C shows reduction in active transport (AT) of free fatty acidsacross the plasma membrane of cells over expressing Mnk2 compared tocontrol cells. All samples were analysed in duplicates (as illustratedby twin bar of identical shadings). PD; passive diffusion illustratedthe baseline or non-energy dependent transportation of exogenous fattyacids across the membrane. AT; active transport represents energydependent transportation of fatty acids across the membrane. The Y-axisshows disintegrations per minutes/mg protein (dpm/mg protein) and theX-axis displays the aforementioned proteins.

FIGS. 9A and 9B show the expression of human Mnk2 in different humantissues.

FIG. 9A shows the expression of human Mnk2A and Mnk2B in different humantissues.

FIG. 9B shows the expression of human Mnk2A and human Mnk2B duringadipocyte differentiation.

FIG. 10 shows the expression of the ectopic mouse Mnk2 (mMnk2DN)transgene in actin-mMnk2DN transgenic mice. Shown is a taqman analysison different tissues isolated from male actin-mMnk2DN transgenic miceand male wild-type littermates. Data are expressed as fold RNA inductionrelative to the corresponding wild-type (wt) tissue. The number on topof each bar indicate the fold induction relative to the corresponding wttissue. Shown is a representative experiment.

FIG. 11 shows that the ectopic mouse Mnk2 (mMnk2DN) expression inactin-mMnk2DN transgenic mice leads to increased body weight Shown aregrowth curves from male bactin-mMnk2DN transgenic mice (dark grey graph)and male wt littermates (light grey graph) on high fat diet over a timeof 10 weeks. Data are expressed as mean body weight overtime+/−SE. Shownis a representative experiment with N=8 respectively N=10 mice pergroup.

FIG. 12 shows the exon/intron boundaries of the mouse Mnk2 geneExon/intron boundaries of the mouse Mnk2 gene are illustrated in thisfigure. Exon numbers, the position of the exons on the cDNA (GenBankaccession number BC010256) and intron lengths are indicated. Intronsequences are shown in lowercase letters, exon sequences are shown incapital, bold letters.

FIG. 13 illustrates the targeted deletion of the mouse Mnk2 gene byhomologous recombination. The top line shows the wild type locus ofmouse Mnk2, the graphic in the middle shows the targeting vector, andthe graphic at the bottom part of the figure illustrates the targetedlocus. The exons are shown as black boxes. Restriction sites,translation start site, and stop codon are indicated. The PGK-NEOcassette and the TK cassette are shown as grey boxes. 4.4 kb of genomicregion of the mouse Mnk2 gene is replaced by a PGK NEO cassette. Thedeleted region is indicated. The outside flanking probe used forSouthern blot analysis is shown by a black bar. The genomic fragmentsdetected with this probe on EcoR1 digested DNA are shown as arrows. Seeexamples for more detail.

FIG. 14 shows that purified Mnk2a can be activated in vitro with apreparation of the kinases Erk2 and the double point mutant Mek1 S218DS222E.

The Examples illustrate the invention:

EXAMPLE 1 Measurement of Triglyceride Content of Homozygous Flies (FIG.1)

The change of triglyceride content of Drosophila melanogaster containinga special expression system (EP-element, Rorth P, Proc Natl Acad Sci USA1996, 93(22): 12418-22) was measured. Mutant flies are obtained from afly mutation stock collection. The flies are grown under standardconditions known to those skilled in the art, and in the course of theexperiment, additional feedings with bakers yeast (Saccharomycescerevisiae) are provided. Specifically, homozygous male EP(3)3333 andEP(3)3576 flies were investigated in comparison to control flies (FIG.1). For determination of triglyceride content, flies were incubated for5 min at gooc in an aqueous buffer using a waterbath, followed by hotextraction. After another 5 min incubation at 90° C. and mildcentrifugation, the triglyceride content of the flies extract wasdetermined using Sigma Triglyceride (I NT 336-10 or -20) assay bymeasuring changes in the optical density according to the manufacturer'sprotocol. As a reference protein content of the same extract wasmeasured using BIO-RAD DC Protein Assay according to the manufacturer'sprotocol. The assay was repeated several times. The average triglyceridelevel of EP collection is shown as 100% in FIG. 1. EP(3)3333 andEP(3)3576 homozygous flies show constantly a higher triglyceride contentthan the controls (approx. 140%). Therefore, the change of gene activityin the locus 86F7 (estimated), where the EP-vector of EP(3)3333 andEP(3)3576 flies is homozygous viably integrated into the Lk6 gene locus,is responsible for changes in the metabolism of the energy storagetriglycerides, therefore representing in both cases an obese fly model.

EXAMPLE 2 Identification of the Drosophila Gene Responsible for theChange in the Metabolism of the Energy Storage Triglycerides (FIG. 2)

Genomic DNA sequences were isolated that are localized directly adjacentto the integration of the EP vectors (herein EP(3)3333 and EP(3)3576).Using those isolated genomic sequences, public databases like BerkeleyDrosophila Genome Project (GadFly) were screened thereby confirming thehomozygous viable integration site of the EP(3)3333 and EP(3)3576vectors. FIG. 2 shows the molecular organization of this gene locus. InFIG. 2, genomic DNA sequence is represented by the assembly as a dottedblack line (from position 7544500 to 7559500 on chromosome 3R) thatincludes the integration sites of EP(3)3333 and EP(3)3576. TranscribedDNA sequences (expressed sequence tags, ESTs) and predicted exons areshown as bars in the lower two lines. Predicted exons of gene CG17342(GadFly, Lk6, homologous to Mnk) are shown as dark grey bars and intronsare shown as slim grey lines in the middle of the figure. Using plasmidrescue method genomic DNA sequences that are directly localised 3′ ofthe EP(3)3333 and EP(3)3576 integration site were isolated. Using theplasmid rescue DNA public DNA sequence databases were screened therebyidentifying the integration site of EP(3)3333 and EP(3)3576 causing anincrease of triglyceride content. EP(3)3333 is integrated in the 5′region of a 5 prime exon of the gene CG17342 and EP(3)3576 in the 5′region of an alternative 5′ exon. Mnk encodes for a gene that ispredicted by GadFly sequence analysis programs as CG17342. Therefore,expression of the CG17342 could be affected by homozygous viableintegration of the EP(3)3333 and EP(3)3576 leading to increase of theenergy storage triglycerides and a change of uncoupling proteinactivity.

EXAMPLE 3 Cloning of a Drosophila melanogaster Gene with Homology toHuman Uncoupling Proteins (UCPs) (FIG. 7)

Sequences homologous to human UCP2 and UCP3 genes were identified usingthe publicly available program BLAST of the data base of the NationalCenter for Biotechnology Information (NCBI) (see, Altschul et al., 1997,Nucleic Acids Res. 25:3389-3402). The homology search yielded sequencefragments of a family of Drosophila genes with UCP homology. They areclearly different to the next related mitochondrial proteins(oxoglutarate carrier). Using the sequence fragment of one of this genes(herein referred to as dUCPy′), a PCR primer pair was generated (Upper5′-CTAAACAAACAATTCCAAACATAG (SEQ ID NO: 9), Lower 5prime—AAAAGACATAGAAAATACGATAGT (SEQ ID NO: 10)) and a PCR reactionperformed on Drosophila cDNA using standard PCR conditions. Theamplification product was radioactively labelled and used to screen acDNA library prepared from adult Drosophila flies (Stratagene). Afull-length cDNA clone was isolated, sequenced (FIG. 7), and used forfurther experiments. The nucleotide sequence of dUCPy is shown in FIG.7A (SEQ ID NO: 7), the deduced open reading is shown in FIG. 7B (SEQ IDNO: 8).

EXAMPLE 4 Cloning of the dUCPy cDNA into an Drosophila Expression Vector

In order to test the effects of dUCPy expression in Drosophila cells,the dUCPy cDNA was cloned into the expression vector pUAST (Brand A &Perrimon N, Development 1993, 118:401-415) using the restriction sitesNot I and Kpn I. The resulting expression construct was injected intothe germline of Drosophila embryos and Drosophila strains with a stableintegration of the construct were generated. Since the expression vectorpUAST is activated by the yeast transcription factor Ga14 which isnormally absent from Drosophila cells dUCPy is not yet expressed inthese transgenic animals. If pUAST-dUCPy flies are crossed with a secondDrosophila strain that expresses Ga14 in a tissue specific manner theoffspring flies of this mating will express dUCPy in the Ga14 expressingtissue. The cross of pUAST-dUCPy flies with a strain that expresses Ga14in all cells of the body (under control of the actin promoter) showed noviable offspring. This means that dUCPy overexpression in all body cellsis lethal. This finding is consistent with the assumption that dUCPyoverexpression could lead to a collapse of the cellular energyproduction. Expression of dUCPy in a non-vital organ like the eye (Ga14under control of the eye-specific promoter of the “eyeless” gene)results in flies with visibly damaged eyes. This easily visible eyephenotype is the basis of a genetic screen for gene products that canmodify UCP activity.

EXAMPLE 5 dUCPy Modifier Screen (FIG. 4)

Parts of the genomes of the strain with Gal4 expression in the eye andthe strain carrying the pUAST-dUCPy construct were combined on onechromosome using genomic recombination. The resulting fly strain haseyes that are permanently damaged by dUCPy expression. Flies of thisstrain were crossed with flies of a large collection of mutagenized flystrains. In this mutant collection a special expression system(EP-element, see Rorth, 1996, supra) is integrated randomly in differentgenomic loci. The yeast transcription factor Ga14 can bind to theEP-element and activate the transcription of endogenous genes close theintegration site of the EP-element. The activation of the genestherefore occurs in the same cells (eye) that overexpress dUCPy. Sincethe mutant collection contains several thousand strains with differentintegration sites of the EP-element it is possible to test a largenumber of genes whether their expression interacts with dUCPy activity.In case a gene acts as an enhancer of UCP activity the eye defect willbe worsened; a suppressor will ameliorate the defect (see FIG. 4). Usingthis screen a gene with enhancing activity was discovered that was foundto be the LK6 kinase in Drosophila.

EXAMPLE 6 Cloning of Lk6 from Drosophila (FIG. 3A)

Genomic DNA neighbouring to the eye-defect rescuing EP-element wascloned by inverse PCR and sequenced. This sequence was used for a BLASTsearch in a public Drosophila gene database. The amino acid sequence ofthe Drosophila protein is shown in FIG. 3A (referred to as dmAAB18789).

EXAMPLE 7 Identification of Mammalian LK6 Homologous Proteins (FIG. 3)

Sequences homologous to Drosophila Lk6 were identified using thepublicly available program BLASTP 2.2.3 of the non-redundant proteindata base of the National Center for Biotechnology Information (NCBI)(see, Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402). Mnkhomologous proteins and nucleic acid molecules coding therefore areobtainable from insect or vertebrate species, e.g. mammals or birds.Particularly preferred are human Mnk homologous polypeptides and nucleicacids, particularly polypeptides and nucleic acids encoding a human Mnk2protein (Genbank Accession No. AF237775 and NM_(—)017572.1; GenbankAccession No. AF237775 is identical to formerly Genbank Accession No.XM_(—)030637 which was removed at the submitters request; see a ClustalW multiple sequence alignment in FIG. 3B) or nucleic acids encoding ahuman Mnk1 protein (Genbank Accession No. AB000409.1 and NM_(—)003684.2;Genbank Accession No. AB000409.1 is identical to formerly GenbankAccession No. XM_(—)001600 which was removed at the submitters request;see a Clustal W multiple sequence alignment in FIG. 3C). FIG. 3A showsthe alignment of the Mnk proteins from different species, hXP_(—)030637refers to human Mnk2 (identical to Genbank Accession No. AF237775),hXP_(—)001600 refers to human Mnk1 (identical to Genbank Accession No.AB000409.1), and dmAB18789 refers to the protein encoded by Drosophilagene with GadFly Accession No. CG17342. The mouse homologouspolypeptides of the invention were identified as GenBank AccessionNumbers NP_(—)067437.1 (for the mouse homolog MAP kinase-interactingserine/threonine kinase 2; Mnk2; for the cDNA GenBank Accession NumberBC010256) and GenBank Accession Numbers NP_(—)067436.1 (for the mousehomolog MAP kinase-interacting serine/threonine kinase 1; Mnk1).

EXAMPLE 8 Expression of the Polypeptides in Mammalian (Mouse) Tissues(FIG. 5 and FIG. 6)

For analyzing the expression of the polypeptides disclosed in thisinvention in mammalian tissues, several mouse strains (preferably micestrains C57BI/6J, C57BI/6 ob/ob and C57BI/KS db/db which are standardmodel systems in obesity and diabetes research) were purchased fromHarlan Winkelmann (33178 Borchen, Germany) and maintained under constanttemperature (preferably 22° C.), 40 percent humidity and a light/darkcycle of preferably 14/10 hours. The mice were fed a standard chow (forexample, from ssniff Spezialitaten GmbH, order number ssniff M-ZV1126-000). For the fasting experiment (“fasted wild type mice”), wildtype mice were starved for 48 h without food, but only water supplied adlibitum. (see, for example, Schnetzler et al. J Clin Invest 1993 July;92(1):272-80, Mizuno et al. Proc Natl Acad Sci USA 1996 Apr. 16;93(8):3434-8). Animals were sacrificed at an age of 6 to 8 weeks. Theanimal tissues were isolated according to standard procedures known tothose skilled in the art, snap frozen in liquid nitrogen and stored at−80° C. until needed. For analyzing the role of the proteins disclosedin this invention in the in vitro differentiation of different mammaliancell culture cells for the conversion of pre-adipocytes to adipocytes,mammalian fibroblast (3T3-L1) cells (e.g., Green & Kehinde, Cell 1:113-116, 1974) were obtained from the American Tissue Culture Collection(ATCC, Hanassas, Va., USA; ATCC-CL 173). 3T3-L1 cells were maintained asfibroblasts and differentiated into adipocytes as described in the priorart (e.g., Qiu. et al., J. Biol. Chem. 276:11988-95, 2001; Slieker etal., BBRC 251: 225-9, 1998). In brief, cells were plated in DMEM/1 0%FCS (Invitrogen, Karlsruhe, Germany) at 50,000 cells/well in duplicatesin 6-well plastic dishes and cultured in a humidified atmosphere of 5%CO₂ at 37° C. At confluence (defined as day 0: dO) cells weretransferred to serum-free (SF) medium, containing DMEM/HamF12 (3:1;Invitrogen), Fetuin (300 μg/ml; Sigma, Munich, Germany), Transferrin (2μg/ml; Sigma), Pantothenate (17A1; Sigma), Biotin (1 _(m)M; Sigma), andEGF (0.8 nM; Hoffmann-La Roche, Basel, Switzerland). Differentiation wasinduced by adding Dexamethasone (DEX; 1 μM; Sigma),3-Methyl-Isobutyl-1-Methylxanthine (MIX; 0.5 mM; Sigma), and bovineInsulin (5 μg/ml; Invitrogen). Four days after confluence (d4), cellswere kept in SF medium, containing bovine Insulin (5 μg/ml) untildifferentiation was completed. At various time points of thedifferentiation procedure, beginning with day 0 (day of confluence) andday 2 (hormone addition; for example, dexamethason and3-isobutyl-1-methylxanthin), up to 10 days of differentiation, suitablealiquots of cells were taken every two days. Alternatively, mammalianfibroblast 3T3-F442A cells (e.g., Green & Kehinde, Cell 7: 105-113,1976) were obtained from the Harvard Medical School, Department of CellBiology (Boston, Mass., USA). 3T3-F442A cells were maintained asfibroblasts and differentiated into adipocytes as described previously(Djian, P. et al., J. Cell. Physiol., 124:554-556, 1985). At varioustime points of the differentiation procedure, beginning with day 0 (dayof confluence and hormone addition, for example, Insulin), up to 10 daysof differentiation, suitable aliquots of cells were taken every twodays. 3T3-F442A cells are differentiating in vitro already in theconfluent stage after hormone (insulin) addition. TaqMan Analysis of theproteins of the invention was carried out (FIG. 5 and FIG. 6). RNA wasisolated from mouse tissues or cell culture cells using Trizol Reagent(for example, from Invitrogen, Karlsruhe, Germany) and further purifiedwith the RNeasy Kit (for example, from Qiagen, Germany) in combinationwith an DNase-treatment according to the instructions of themanufacturers and as known to those skilled in the art. Total RNA wasreverse transcribed (preferably using Superscript II RNaseH-ReverseTranscriptase, from Invitrogen, Karlsruhe, Germany) and subjected toTaqman analysis preferably using the Taqman 2xPCR Master Mix (fromApplied Biosystems, Weiterstadt, Germany; the Mix contains according tothe Manufacturer for example AmpliTaq Gold DNA Polymerase, AmpErase UNG,dNTPs with dUTP, passive reference Rox and optimized buffer components)on a GeneAmp 5700 Sequence Detection System (from Applied Biosystems,Weiterstadt, Germany).

For the analysis of the expression of Mnk2 or Mnk1, taqman analysis wasperformed using the following primer/probe pairs:

Mouse Mnk1 forward primer (Seq ID NO: 11) 5′-GCT GAG GGC CTC TGC TCC-3′;Mouse Mnk1 reverse primer (Seq ID NO: 12) 5′-TCG CCT TCG AGC GAG G-3′;Mouse Mnk1 Taqman probe (Seq ID NO: 13)(5/6-FAM) TGAAGCTGTCCCCTCCATCCAAATCTC (5/6-TAMRA)Taqman-1856F Mnk2 forward primer (SEQ ID NO: 14):5′-TGCACTTGATTGACCCCGA-3′Taqman-1923R Mnk2 reverse primer (SEQ ID NO: 15):5′-TTTCTGATTGTCAACCCTCCAA-3′Taqman-1877T Mnk2 Taqman probe (SEQ ID NO: 16):(5/6-FAM)-CCCCATCATCCACCTGCAGTGTCC-(5/6-TAMRA)

Taqman analysis revealed that Mnk2 is the more interesting homologue ofthe fly Lk6 gene. The results are shown in FIG. 5 and FIG. 6. Incomparison to Mnk1, which is rather ubiquitously expressed, Mnk2 showsits highest expression levels in the brown and white adipose tissues(FIGS. 5A and 6A, respectively). The expression of Mnk2 in white adiposetissue is under metabolic control: In fasted as well as obese (ob/ob)mice, expression is reduced to about 40% of wildtype levels (FIG. 5C;see also FIG. 58). In addition, expression of Mnk2 is strongly inducedduring the in vitro differentiation of 3T3-L 1 (FIG. 50) as well as oftwo additional model systems for the in vitro differentiation ofpreadipocytes to adipocytes, the 3T3-F442A and TA1 cell lines (FIG. 5Eand FIG. 5F, respectively). Contrary to this, the relative expressionlevels of Mnk1 remain unchanged during the differentiation of these celllines (FIGS. 6D and 6E, respectively).

EXAMPLE 9 Expression of the Polypeptides in Mammalian (Human) Tissues(FIG. 9)

Human primary adipocytes were differentiated into mature adipocytes asdescribed by Hauner et al. 1989 (J Clin Invest 84(5): 1663-70). Briefly,cells were grown in DMEM/Nutrient Mix F12, 1% PenStrep, 17 μM Biotin, 33μM Pantothenat, 10% none heat inactivated fetal calf serum. On day 0 ofdifferentiation, the medium was changed to OM EM/Nutrient Mix F12, 1%Pen/Strep, 17 μM Biotin, 33 μM Pantothenat, 0.01 mg/ml Transferrin,Hydrocortisone, 20 nM humanes Insulin, 0.2 nM T3.25 nM Dexamethasone,250 μlM IBMX, 3 μM Rosiglitazone. On day 4 of differentiation, themedium was changed to DMEM/Nutrient Mix F12 1% Pen/Strep, 17 μM Biotin,33 μM Pantothenat, 0.01 mg/ml Transferrin, 100 nM Hydrocortisone, 20 nMhumanes Insulin, 0.2 nM T3. At various time points of thedifferentiation procedure, beginning with day 0 (day of confluence) andday 4 (hormone addition), up to 14 days of differentiation, suitablealiquots of cells were taken every two days. RNA was isolated from humancell culture cells using Trizol Reagent (for example, from Invitrogen,Karlsruhe, Germany) and further purified with the RNeasy Kit (forexample, from Qiagen, Germany) in combination with an DNase-treatmentaccording to the instructions of the manufacturers and as known to thoseskilled in the art. In addition to the RNA isolated from humanadipocytes at different differentiation stage, RNAs isolated fromdifferent human tissues were obtained from Invitrogen Corp., Karlsruhe,Germany: (i) total RNA from human adult skeletal muscle (InvitrogenCorp. Order Number 735030); (ii) total RNA from human adult lung(Invitrogen Corp. Order Number 735020); (iii) total RNA from human adultliver (Invitrogen Corp. Order Number 735018); (iv) total RNA from humanadult placenta (Invitrogen Corp. Order Number 735026); (v) total RNAfrom human adult testis (Invitrogen Corp. Order Number 641 01-1); (vi)total RNA from human normal adipose tissue (Invitrogen Corp. OrderNumber 06005-01); (vii) total RNA from human normal pancreas (InvitrogenCorp. Order Number DG61 01); (viii) total RNA from human normal brain(Invitrogen Corp. Order Number 06030-01). The RNA was treated with DNaseaccording to the instructions of the manufacturers (for example, fromQiagen, Germany) and as known to those skilled in the art. Total RNA wasreverse transcribed (preferably using Superscript II RNaseH-ReverseTranscriptase, from Invitrogen, Karlsruhe, Germany) and subjected toTaqman analysis preferably using the Taqman 2xPCR Master Mix′ (page 66,line 31: Weiterstadt, Germany; see Example 8). Taqman analysis wasperformed preferably using the following primer/probe pairs:

For the amplification of human Mnk2a:

human Mnk2a forward primer (SEQ ID NO: 17):5′-cca tct ccc cct ctg tac ata gg-3′;human Mnk2a reverse primer (SEQ ID NO: 18):5′-ccg get ggc gat age tta a-3′; Taqman probe (SEQ ID NO: 19):(5/6-FAM) cac ccg tee ccc aat caa ate taa agg (5/6-TAMRA)

For the amplification of human Mnk2b:

human Mnk2b forward primer (SEQ ID NO: 20):5′-TTA CTG TGA ATG AGT GAA GAT CCT GG-3′;human Mnk2b reverse primer (SEQ ID NO: 21 ):5′-ATG GCC GTT CAC CGT CC-3′; Taqman probe (SEQ ID NO: 22):(5/6-FAM) CCA GGC GAG CTC CCA TCG CTG (5/6-TAMRA)

As shown in FIG. 9A, real time PCR (Taqman) analysis of the expressionof Mnk2a and Mnk2b protein in human tissues revealed that both proteinsare expressed in all tissues analysed with high levels of expression inadipose tissue, muscle, lung, testis, and placenta. The relativeexpression levels of both human Mnk2 splice variants is the same for alltissues analysed. Both show highest expression levels in tissuesrelevant for metabolic disorders namely adipose and muscle tissue. Asshown in FIG. 9B, Mnk2a as well as Mnk2b are upregulated during humanadipocyte differentiation. This suggests a function of both proteins inthe metabolism of mature adipocytes.

EXAMPLE 10 Assays for the Determination of Triglyceride Storage,Synthesis and Transport (FIG. 8) Retroviral Infection of Preadipocytes

Packaging cells were transfected with retroviral plasmids pLPCX carryingmouse Mnk2 transgene and a selection marker using calcium phosphateprocedure. Control cells were infected with pLPCX carrying no transgene.Briefly, exponentially growing packaging cells were seeded at a densityof 350,000 cells per 6-well in 2 ml DMEM+10% FCS one day beforetransfection. 10 min before transfection chloroquine was added directlyto the overlying medium (25 μM final concentration). A 250 μltransfection mix consisting of 5 μg plasmid-DNA (candidate: helper-virusin a 1:1 ratio) and 250 mM CaCl₂ was prepared in a 15 ml plastic tube.The same volume of 2×HBS (280 μM NaCl, 50 μM HEPES, 1.5 mM Na₂HPO₄, pH7.06) was added and air bubbles were injected into the mixture for 15sec. The transfection mix was added drop wise to the packaging cells,distributed and the cells were incubated at 37° C., 5% CO₂ for 6 hours.The cells were washed with PBS and the medium was exchanged with 2 mlDMEM+10% CS per 6-well. One day after transfection the cells were washedagain and incubated for 2 days of virus collection in 1 ml DMEM+10% CSper 6-well at 32° C., 5% CO₂. The supernatant was then filtered througha 0.45 μm cellulose acetate filter and polybrene (final concentration 8μg/ml) was added. Mammalian fibroblast (3T3-L1) cells in a sub-confluentstate were overlaid with the prepared virus containing medium. Theinfected cells were selected for 1 week with 2 1-Jg/ml puromycin.Following selection the cells were checked for transgene expression bywestern blot and immunofluorescence. Over expressing cells were seededfor differentiation. 3T3-L 1 cells were maintained as fibroblasts anddifferentiated into adipocytes as described in the prior art and inexample 8. For analysing the role of the proteins disclosed in thisinvention in the in vitro assays for the determination of triglyceridestorage, synthesis and transport were performed.

Preparation of Cell Lysates for Analysis of Metabolites

Starting at confluence (DO), cell media was changed every 48 hours.Cells and media were harvested 8 hours prior to media change as follows.Media was collected, and cells were washed twice in PBS prior to lysesin 600 μl HB-buffer (0.5% Polyoxyethylene 10 tridecylethan, 1 mM EDTA,0.01 M NaH₂PO₄, pH 7.4). After inactivation at 70° C. for 5 minutes,cell lysates were prepared on Bio 101 systems lysing matrix B (0.1 mmsilica beads; Q-Biogene, Carlsbad, USA) by agitation for 2×45 seconds ata speed of 4.5 (Fastprep FP120, Bio 101 Thermosavant, Hoi brock, USA).Supernatants of lysed cells were collected after centrifugation at 3000rpm for 2 minutes, and stored in aliquots for later analysis at −80° C.

Changes in cellular triglyceride levels during adipogenesis (FIG. 8A)Cell lysates and media were simultaneously analysed in 96-well platesfor total protein and triglyceride content using the Bio-Rad DC Proteinassay reagent (Bio-Rad, Munich, Germany) according to the manufacturer'sinstructions and a modified enzymatic triglyceride kit (GPO-Trinder;Sigma) briefly final volumes of reagents were adjusted to the 96-wellformat as follows: 10 μl sample was incubated with 200 μl reagent A for5 minutes at 37° C. After determination of glycerol (initial absorbanceat 540 nm), 50 μl reagent B was added followed by another incubation for5 minutes at 37° C. (final absorbance at 540 nm). Glycerol andtriglyceride concentrations were calculated using a glycerol standardset (Sigma) for the standard curve included in each assay.

As shown in FIG. 8A, we found that in Mnk2 overexpressing cells cellulartriglyceride levels were significantly lower from day 4 to day 12 ofadipogenesis compared to that in the control cells (FIG. 8A). Theseresults indicate that Mnk2 targets regulatory pathways or enzymesinvolved in lipid metabolism, which we analysed in more detail in thelipid synthesis and FFA transport assays described below.

Synthesis of Lipids During Adipogenesis (FIG. 8B)

During the terminal stage of adipogenesis (day 12) cells were analysedfor their ability to metabolise lipids. A modified protocol to themethod of Jensen et al (2000), JBC 275, 40148, for lipid synthesis wasestablished. Cells were washed 3 times with PBS prior to serumstarvation in Krebs-Ringer-Bicarbonate-Hepes buffer (KRBH; 134 nM NaCl,3.5 mM KCl, 1.2 mM KH₂PO₄, 0.5 mM MgS04, 1.5 mM CaCl₂, 5 mM NaHCO₃, 10mM Hepes, pH 7.4), supplemented with 0.1% FCS for 2.5 h at 37° C. Forinsulin-stimulated lipid synthesis, cells were incubated with 1 μMbovine insulin (Sigma; carrier: 0.005 N HCl) for 45 min at 37° C. Basallipid synthesis was determined with carrier only. ¹⁴C(U)-D-Glucose (NENLife Sciences) in a final activity of 1 μCi/Well/ml in the presence of 5mM glucose was added for 30 min at 37° C. For the calculation ofbackground radioactivity, 25 μM Cytochalasin B (Sigma) was used. Allassays were performed in duplicate wells. To terminate the reaction,cells were washed 3 times with ice cold PBS, and lysed in 1 ml 0.1 NNaOH. Protein concentration of each well was assessed using the standardBiuret method (Protein assay reagent; Bio-Rad). Total lipids wereseparated from aqueous phase after overnight extraction in Insta-Fiuorscintillation cocktail (Packard Bioscience) followed by scintillationcounting.

Our results clearly show that Mnk2 overexpressing cells were lesseffective at synthesising lipids from exogenous glucose. Consequently,the levels of insulin stimulated lipid synthesis are significantly lowerat day 12 of adipogenesis when compared to control cells (FIG. 8B). Thelower lipid levels observed in the experiments above therefore resultmost likely from a lower lipid synthesis rate and are not the result ofan increased turn over of lipid stores.

Transport and Metabolism of Free Fatty Acids Across During Adipogenesis(FIG. 8C)

During the terminal stage of adipogenesis (D12) cells were analysed fortheir ability to transport long chain fatty acid across the plasmamembrane. A modified protocol to the method of Abumrad et al (1991)(Proc. Natl. Acad. Sci. USA, 1991: 88; 6008-12) for cellulartransportation of fatty acid was established. In summary, cells werewashed 3 times with PBS prior to serum starvation. This was followed byincubation in KRBH buffer, supplemented with 0.1% FCS for 2.5 h at 37°C. Uptake of exogenous free fatty acids was initiated by the addition ofisotopic media containing non radioactive oleate and (³H)oleate (NENLife Sciences) complexed to serum albumin in a final activity of 1μCi/Well/ml in the presence of 5 mM glucose for 30 min at roomtemperature (RT). For the calculation of passive diffusion (PD) in theabsence of active transport (AT) across the plasma membrane 20 mM ofphloretin in glucose free media (Sigma) was added for 30 min at roomtemperature (RT). All assays were performed in duplicate wells. Toterminate the active transport 20 mM of phloretin in glucose free mediawas added to the cells. Cells were lysed in 1 ml 0.1 N NaOH and theprotein concentration of each well were assessed using the standardBiuret method (Protein assay reagent; Bio-Rad). Esterified fatty acidswere separated from free fatty acids using overnight extraction inlnsta-Fiuor scintillation cocktail (Packard Bioscience) followed byscintillation counting.

We found that transport of exogenous fatty acids across the plasmamembrane of Mnk2 overexpressing cells and hence esterification of thesemetabolites were considerably lower at day 12 of adipogenesis whencompared to control cells (FIG. 8C). Taken together the overexpressionof Mnk2 showed an effect on triglyceride metabolism in all three assayswe performed in 3T3-L1 cells, making it a potential interesting drugtarget to treat metabolic disorders.

EXAMPLE 11 Generation and Analysis of Mnk2 Transgenic Animals(I3-Actin-mMnk2DN) Generation of the Transgenic Animals

Mouse Mnk2 cDNA was isolated from mouse brown adipose tissue (BAT) usingstandard protocols as known to those skilled in the art. The cDNA wasamplified by RT-PCR using the following primer pair:

Mnk2 forward primer (SEQ ID NO: 23): 5′ AAG TTG GCC TTC GCG TTA GAG 3′Mnk2 reverse primer (SEQ ID NO: 24): 5′ CGA TAT GTA CAA GGA GCT AG 3′.

The resulting Mnk2 cDNA was cloned into pBluescript KS+ (Stratagene)according to standard protocols, resulting in a plasmid referred to aspKS+-mMnk2′. The cDNA of pKS+-mMnk2 c was mutated using site directedmutatagenesis (Stratagene), according to the manufacturer'sinstructions. Using the Mnk2 top oligo (SEQ ID NO: 25): 5′ CTC CCC CATCTC CGC ACC AGA GCT GCT CGC CCC GTG TGG GTC AG 3′ and the Mnk2 bottomoligo (SEQ ID NO: 26): 5′ CTG ACC CAC ACG GGG CGA GCT CTG GTG CGG AGATGG GGG AG 3′, two point mutations were introduced into the cDNAresulting in amino acid exchanges at position T197 and T202 to A197 andA202 of the Mnk2 cDNA.

The resulting mutated cDNA (referred to as mMnk2DN) was cloned into theEcoRV cloning site of the transgenic expression vectorpTG-β-actin-X-hgh-bgh-polyA. The β-actin-Mnk2DN transgene wasmicroinjected into the male pronucleus of fertilized mouse embryos(preferably strain C57/BL6/CBA F1 (Harlan Winkelmann). Injected embryoswere transferred into pseudo-pregnant foster mice. Transgenic founderswere detected by PCR analysis using the forward primer (SEQ ID NO: 27):5′ GCT GCT GGT CCG AGA TGC C₃′ and reverse primer (SEQ ID NO: 28): 5′GGG TCA TGC GCG ATC CCC 3′. Two independent transgenic mouse linescontaining the β-actin-Mnk2DN construct were established and kept on aC57/BL6 background. Briefly, founder animals were backcrossed withC57/BL6 mice to generate F1 mice for analysis. Transgenic mice werecontinously bred onto the C57/BL6 background.

Expression of the construct in different mouse tissues (FIG. 10) usingstandard techniques, β-actin-Mnk2DN transgene expression was verified byTaqman analysis using forward primer (SEQ ID NO: 29): 5′ GAG CGT GGT AGTACA GGA CGT G 3′, reverse primer (SEQ ID NO: 30): 5′ TCC CTG TGG GCG ATGC₃′ and primer (SEQ ID NO: 31): 5′ GAG TGC CCT GGA CTT CCT GCA TAA CAA3′. Taqman analysis was performed using a representative panel of mousetissues.

The expression of the bactin-Mnk2DN transgene was observed in thefollowing tissues: WAT, muscle, liver, kidney, thymus, heart, lung, andspleen. Expression levels of the transgene were 2.8-16.9 fold increasedrelative to Mnk2 expression in wild-type mice, depending on the tissueanalyzed. No Mnk2 transgene expression was detected in BAT tissue (seeFIG. 10).

Analysis of the Bodyweight of the Transgenic Mice (FIG. 11)

After weaning, male (β-actin-mMnk2DN transgenic mice and their wild-type(wt) littermates controls were placed in groups of 4 to 5 animals (N=4up to N=5) on control diet (preferably Altromin C1057 mod control, 4.5%crude fat or high fat diet (preferably Altromin C1057 mod. high fat,23.5% crude fat). Total body weight of the animals was measured weeklyover a period of 12-16 weeks. On each diet, mean bodyweight of(β-actin-mMnk2DN transgenic mice was clearly increased compared towildtype littermates on the respective diet. Significant differences inmean bodyweight were first observed around the end of postnatal week 4on both diets. After 10 weeks on high fat diet, the mean bodyweight ofβ-actin-mMnk2DN transgenic mice compared to wt littermates was increasedby 8.8 g (=23% increase in mean bodyweight relative to wt littermates)(FIG. 11). Similar differences in mean body weight were observed in wtand β-actin-mMnk2DN transgenic mice on control diet (data not shown).Thus, our results clearly show that the ectopic expression of mMnk2DNtransgene leads to an increase in bodyweight. The effect appearsindependently of the diet give, as it can be seen on control diet aswell as on high fat diet.

EXAMPLE 11 Generation and Analysis of mMnk2 −/− Mice (FIG. 12 and FIG.13)

A 605 base pair probe of the mMnk2 cDNA (GenBank accession numberBC010256; position 61-665) was amplified from mouse white adipose tissue(WAT) cDNA by PCR using forward primer (SEQ ID NO: 32): 5′ ACA TCA GCCCAC AGT GTG A 3′ and reverse primer (SEQ ID NO: 33): 5′ TCT CCA TTG AGTTTG AT A CCA 3′. This probe was used to screen a 129SV J genomic phagelibrary (obtained from Stratagene). Three independent clones wereisolated and subcloned into the NotI cloning site of pBiuescript KS+(Stratagene). These genomic clones were used for restriction mapping andsequencing to characterize the genomic locus of mouse Mnk2 (FIG. 12). APGK-neomycin cassette was inserted into the locus of mouse Mnk2replacing 4.4 kb of genomic DNA thereby deleting the complete codingregion of mMnk2. Briefly, an 8 kb SpeI-NotI fragment was cloned into theXbaI site of pBiuescript KS+ upstream of the PGK-Neomycin cassette,which was inserted into the SmaI site of pBluescript. A 1 kb genomicfragment was amplified by PCR using the following primer pair (nonpriming nucleotides/attached restriction sites are lower case letters):Mnk2-SA forward primer (SEQ ID NO: 34): EcoRI 5′ cgg aat CCA CTA GCT CCTTGT ACA TAT 3′; Mnk2-SA reverse primer (SEQ ID NO: 35): Cla15′ cca tcgatG GAA CTC GTA TTG CAT AGT AG 3′. The resulting fragment was insertedinto the EcoRI/Cia I site of pBluescript KS+. As a negative selectionmarker a thymidine kinase cassette was cloned into ClaI/XhoI site of thetargeting construct. (FIG. 13). The construct was linearized by NotIdigestion and electroporated into mouse embryonic stem (ES) cells. EScell clones were selected by G418 and Gancyclovir treatment (preferably350 μg G4181 ml and 2 μM Gancyclovir). Out of 600 neomycin resistantcolonies, two independent homologous recombined ES cell clones wereidentified by PCR. The results were confirmed by southern blot analysiswith EcoRI digested genomic DNA using a 3′ flanking probe (position2495-3065 mMnk2 cDNA). A single integration event was confirmed bySouthern blot analysis of BamHI digested DNA with a Neomycin probe. EScell clones were aggregated with 8-cell-stage embryos from NMRI mice anddeveloping blastocysts were transferred into pseudo-pregnant mice togenerate chimeras. Chimeras were bred with C57/BL6 mice and offspringswere genotyped by PCR using the following primers: Mnk2-ES primer (SEQID NO: 36): 5′ AGA CTA GGG AGG AGG GTG GAG GA 3′; Mnk2-KO primer (SEQ IDNO: 37): 5′ GGT GGA TGT GGA ATG TGT GCG A 3′; Mnk2-WT 5′ GGG GTG TAG GGGTCT GTT AGG 3′. Heterozygous mice were used for further intercrosses andanalyzed.

EXAMPLE 11 Small Molecule Screening

Compounds which are suitable for the prophylaxis, treatment or diagnosisof Mnk-related metabolic disorders may be identified via a kinase assay,a binding assay or any other suitable assay to measure a functionassociated with the Mnk polypeptide, a Mnk polypeptide fragment orderivative thereof. This kinase assay may be based on recombinant humanMnk2 (Mnk2a or Mnk2b) or Mnk1 protein and a labelled peptide comprisingthe eIF4E target sequence, a labelled recombinant eIF4E target sequenceor a labelled recombinant eiF4E protein as a substrate. The assay may bea radioactive kinase assay or an assay based on using ananti-phosphoserine antibody which is capable of recognizing eIF4Ephosphorylation at Ser209.

For example, the kinases Mnk2a (GenBank Accession Number AF237775; seealso FIGS. 3D and 3E), Erk2 (GenBank Accession Number M84489) and adouble point mutant of Mek1 (GenBank Accession Number 002750) containingthe amino acid substitutions Ser218Asp and Ser222Glu (S218D S222E) wereexpressed in E. coli and subsequently purified using methods known tothose skilled in the art. Preferably, in a kinase reaction of 50 p1, 2.0μM Mnk2a was incubated with 200 nM Erk2 plus 20 nM Mek1 S218D S222E(labelled lanes 1 to 4 in FIG. 14) or with 50 nM Erk2 plus 2.5 nM Mek1S218D S222E (labelled lanes 5 to 8 in FIG. 14) in the presence of 1.0 mMATP, 50 mM Hepes/KOH, mM magnesium chloride and 0.5 mM OTT at 30° C. Atthe indicated time points (0, 10, 20 and 40 minutes, see FIG. 14),samples were taken from the reaction, diluted in SDS sample buffercontaining 50 mM EDTA and separated by SDS polyacrylamide gelelectrophoresis (SDS-PAGE). SDS-PAGE separated reaction samples wereblotted onto nitrocellulose and probed with an antibody against aphospho-eptipe, essential for the activation of Mnk (anti-Phospho-MnkThr197/202; Cell Signaling Technology, Inc., Beverly, Mass.). Theanti-Phospho-Mnk antibody was detected with a peroxidase-coupled antirabbit antibody (Sigma-Aldrich, St. Louis, Mo.) as described elsewhere(Harlow and Lane, 1998, Antibodies, Cold Spring Harbor Laboratory Press,NY).

As the reaction progresses, the activation of Mnk2a can be visualized byMnks immuno-reactivity with the anti Phospho-Mnk antibody (see upperpanel in FIG. 14). In addition, Mnk2a was visualized by Coomassiestaining of the gel. Arrows indicate the Coomassie stained Mnk2a as itsmobility is retarded with increasing phosphorylation (see lower panel inFIG. 14).

The generation of the phospho-epitope, essential for the activation ofMnk2a, and the high degree of efficiency of this process (as shown bythe nearly complete electrophoretic mobility shift) demonstrate thesuitability of this approach to produce enzymatically active Mnk2a.

For the validation of the assay, known Mnk inhibitors such as CGP57380or CGP025088 may be used (see, Knauf et al., 2001, Mol. Cell. Biol.21:5500, Tschopp et al., 2000, Mol Cell Biol Res Comm 3:205 andSlentz-Kesler et al., 2000, Genomics 69:63). As a negative control,CGP052088 may be used.

Alternatively, the screening may comprise the use of cellular basedscreening systems, e.g. prokaryotic or eukaryotic cells whichoverexpress Mnk proteins. Furthermore, transgenic animals capable ofoverexpressing or underexpressing Mnk2 and/or Mnk1 may be used.

All publications and patents mentioned in the above specification areherein incorporated by reference.

Various modifications and variations of the described method and systemof the invention will be apparent to those skilled in the art withoutdeparting from the scope and spirit of the invention. Although theinvention has been described in connection with specific preferredembodiments, it should be understood that the invention as claimedshould not be unduly limited to such specific embodiments. Indeed,various modifications of the described modes for carrying out theinvention which are obvious to those skilled in molecular biology orrelated fields are intended to be within the scope of the followingclaims.

We claim:
 1. A method of identifying an animal or human subject havingan elevated probability of having or developing a pancreaticmalfunction, the method comprising the steps of: (a) obtaining abiological sample from an animal or human subject; and (b) determiningfrom the biological sample whether the animal or human subject has agenetic variant of an Mnk2 gene and/or Mnk1 gene or a homolog thereof,or an expression product of said Mnk2 gene and/or Mnk1 gene or homologthereof, wherein said genetic variant is associated with an elevatedprobability of having or developing a pancreatic malfunction.
 2. Themethod of claim 2, wherein the pancreatic malfunction is characterizedas diabetes.
 3. The method of claim 1, wherein step (b) comprisesisolating a nucleic acid from the biological sample and determining fromthe nucleotide sequence thereof whether the biological sample includes agenetic variant of an Mnk2 gene or a homolog thereof, wherein saidgenetic variant is associated with an elevated probability of having ordeveloping a pancreatic malfunction.
 4. The method of claim 1, whereinstep (b) comprises determining whether a polypeptide expression productof the Mnk2 gene, or a homolog thereof, is expressed from a genomic genevariant associated with an elevated probability of having or developinga pancreatic malfunction.
 5. The method of claim 3, wherein step (b)further comprises isolating a nucleic acid from the biological sampleand determining whether the biological sample has the Mnk2a geneticvariant, the Mnk2b genetic variant, or a combination thereof.
 6. Themethod of claim 5, wherein the Mnk2a and the Mnk2b genetic variants aredetected by real-time PCR analysis.
 7. The method of claim 6, whereinthe real-time PCR analysis uses the human Mnk2a forward primer (SEQ IDNO: 17), the human Mnk2a reverse primer (SEQ ID NO: 18), and the Taqmanprobe (SEQ ID NO: 19).
 8. The method of claim 6, wherein the real-timePCR analysis uses the human Mnk2b forward primer (SEQ ID NO: 20), thehuman Mnk2b reverse primer (SEQ ID NO: 21), and the Taqman probe (SEQ IDNO: 22).
 9. The method of claim 3, wherein the determination of whethera polypeptide expression product of the Mnk2 gene, or a homolog thereof,is expressed from a genomic gene variant associated with an elevatedprobability of having or developing a pancreatic malfunction comprisesdetecting a polypeptide expressed from the Mnk2a variant, the Mnk2bvariant, or a combination thereof.
 10. The method of claim 9, whereindetecting a polypeptide expressed from the Mnk2a variants, the Mnk2bvariant, or a combination thereof, comprises contacting the biologicalsample, or a population of polypeptides isolated therefrom, with atleast one antibody specifically recognizing the Mnk2a variant, the Mnk2bvariant, or a combination thereof.
 11. The method of claim 1, whereinstep (b) further comprises the steps of: (i) isolating a population ofcells from the biological sample and optionally culturing said cells toexpand the population; (ii) dividing the population of cells into afirst aliquot of cells and a second aliquot of cells; (iii) determiningthe level of Mnk2 activity and/or Mnk1 activity in the first aliquot ofcells; (ii) contacting the second aliquot of cells with an iRNAspecifically hybridizing to a genetic variant of Mnk2 and/or Mnk1 anddetermining the level of Mnk2 activity and/or Mnk1 activity of thesecond aliquot of cells; and (v) comparing the level of Mnk activitiesin the first and the second aliquots of cells, wherein if the level ofMnk2 activity and/or Mnk1 activity in the second aliquot is less than inthe first aliquot, the nucleotide sequence of the iRNA identifies thegenetic variant of the Mnk2 gene and/or Mnk1 gene in the biologicalsample.
 12. A method of reducing the level of a pancreatic malfunctionin a patient by administering to said patient a pharmaceuticallyacceptable composition comprising a heterologous nucleic acid, whereinsaid heterologous nucleic acid modulates the level of activity of avariant Mnk gene, and/or an antibody recognizing a polypeptide encodedby a variant Mnk gene, thereby reducing a pancreatic malfunction in therecipient patient.
 13. The method of claim 12, wherein the pancreaticmalfunction is characterized as diabetes.
 14. The method of claim 12,wherein the heterologous nucleic acid is selected from the groupconsisting of a nucleotide sequence encoding a variant Mnk2, anantisense molecule, a ribozyme, and an iRNA recognizing an Mnk2 nucleicacid.
 15. The method of claim 12, wherein the nucleotide sequenceencoding a variant Mnk2 is operably connected to a gene expressionregion and optionally inserted in a vector suitable for delivery of theheterologous nucleic acid to a cell of the recipient patient andexpression of the nucleotide sequence encoding a variant Mnk2polypeptide in the recipient patient.
 16. The method of claim 12,wherein the nucleotide sequence encoding a variant Mnk2 encodes Mnk2b oran enzymatically active variant thereof.
 17. The method of claim 12,wherein the nucleotide sequence encoding a variant Mnk2 encodes Mnk2a oran enzymatically active variant thereof.
 18. The method of claim 12,wherein the heterologous nucleic acid encodes an antisense molecule, aribozyme, or an iRNA.
 19. The method of claim 18, wherein theheterologous nucleotide sequence is operably connected to an expressionpromoter region and optionally inserted in a vector suitable fordelivery of the heterologous nucleic acid to a cell of the recipientpatient and expression of the heterologous nucleotide sequence therein,thereby reducing the expression of a variant Mnk gene.
 20. The method ofclaim 18, wherein the heterologous nucleic acid specifically hybridizesto a nucleotide sequence encoding a region of the Mnk2b gene variant, orthe antisence sequence thereof under high stringency conditions.
 21. Themethod of claim 13, wherein the pharmaceutically acceptable compositionfurther comprises a pharmaceutically acceptable carrier, apharmaceutically acceptable diluent, a pharmaceutically acceptableadjuvant, or any combination thereof.
 22. A pharmaceutically acceptablecomposition comprising: (i) a heterologous nucleic acid, wherein saidheterologous nucleic acid modulates the level of activity of a variantMnk gene when delivered to a cell of a patient, and/or an antibodyrecognizing a polypeptide encoded by a variant Mnk gene, therebyreducing a pancreatic malfunction in the recipient patient; and (ii) apharmaceutically acceptable carrier, a pharmaceutically acceptablediluent, a pharmaceutically acceptable adjuvant, or any combinationthereof.
 23. A method of screening for an agent which modulates theactivity of an Mnk homologous polypeptide, comprising the steps of: (a)incubating a mixture comprising: (aa) an Mnk homologous polypeptide, ora fragment thereof; and (ab) a candidate agent, under conditions wherebysaid Mnk polypeptide or fragment thereof exhibits a reference activity;(b) detecting the activity of said Mnk polypeptide or fragment thereofto determine an candidate agent-biased activity, and (c) determining adifference between a candidate agent-biased activity and the referenceactivity, thereby identifying an agent as a modifier of the interactionof an Mnk homologous polypeptide with a binding target/agent, which isassociated with pancreatic malfunction.
 24. The method of claim 23,wherein the Mnk homologous polypeptide is a Mnk2 homologous polypeptide.25. The method of claim 23, wherein the candidate agent is selected frompeptides and low-molecular weight organic compounds.
 26. The method ofclaim 23, wherein a known Mnk effector is used as a positive control forassay development and/or validation of candidate agents.